[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1017
1. Avenel P, McKendrick A, Silapaswan S, Kolachalam R, Kestenberg W, Ferguson L, Jacobs MJ, Goriel Y, Mittal V: Gastrointestinal carcinoids: an increasing incidence of rectal distribution. Am Surg; 2010 Jul;76(7):759-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Other sites of carcinoid tumors were the appendix (8.3%), colon (8.3%), and duodenum (3.8%).
  • CT was not helpful in preoperative diagnosis of carcinoid tumor.
  • Fifteen patients died in follow-up with eight deaths related to carcinoid tumors, in the small bowel (6), rectum (1), and colon (1).
  • Screening colonoscopy, in addition to decreasing colorectal adenocarcinoma mortality, is useful in diagnosing carcinoid tumors at an earlier stage and in decreasing mortality from malignant colorectal carcinoid tumors.

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20698387.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Meca G, Ruiz MJ, Soriano JM, Ritieni A, Moretti A, Font G, Mañes J: Isolation and purification of enniatins A, A(1), B, B(1), produced by Fusarium tricinctum in solid culture, and cytotoxicity effects on Caco-2 cells. Toxicon; 2010 Sep 1;56(3):418-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cytoxicity of the ENs was tested in the cell lines of human origin (epithelial colorectal adenocarcinoma cells, Caco-2) by MTT assays.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20417655.001).
  • [ISSN] 1879-3150
  • [Journal-full-title] Toxicon : official journal of the International Society on Toxinology
  • [ISO-abbreviation] Toxicon
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Depsipeptides; 0 / enniatins
  •  go-up   go-down


3. Sakuma S, Yano T, Masaoka Y, Kataoka M, Hiwatari K, Tachikawa H, Shoji Y, Kimura R, Ma H, Yang Z, Tang L, Hoffman RM, Yamashita S: Detection of early colorectal cancer imaged with peanut agglutinin-immobilized fluorescent nanospheres having surface poly(N-vinylacetamide) chains. Eur J Pharm Biopharm; 2010 Mar;74(3):451-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of early colorectal cancer imaged with peanut agglutinin-immobilized fluorescent nanospheres having surface poly(N-vinylacetamide) chains.
  • PNA is a targeting moiety that binds to beta-D-galactosyl-(1-3)-N-acetyl-D-galactosamine, which is the terminal sugar of the Thomsen-Friedenreich antigen that is specifically expressed on the mucosal side of colorectal cancer cells.
  • The in vivo performance of the imaging agent was evaluated using a human colorectal cancer orthotopic animal model.
  • Human colorectal adenocarcinoma cell lines, HT-29, HCT-116, and LS174T, were implanted on the cecal serosa of immune-deficient mice.
  • [MeSH-major] Acetamides / chemistry. Colorectal Neoplasms / diagnosis. Diagnostic Imaging / methods. Fluorescent Dyes / chemistry. Nanospheres / chemistry. Peanut Agglutinin / chemistry. Polyvinyls / chemistry
  • [MeSH-minor] Animals. Cecum / pathology. Cell Line, Tumor. Colitis / diagnosis. Colitis / pathology. Colon / pathology. Early Detection of Cancer / methods. Female. Intestinal Mucosa / pathology. Luminescent Proteins / chemistry. Luminescent Proteins / genetics. Mice. Mice, Nude. Mice, SCID. Microscopy, Fluorescence. Molecular Structure. Neoplasm Transplantation. Particle Size. Surface Properties

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20060903.001).
  • [ISSN] 1873-3441
  • [Journal-full-title] European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik e.V
  • [ISO-abbreviation] Eur J Pharm Biopharm
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Acetamides; 0 / Fluorescent Dyes; 0 / Luminescent Proteins; 0 / Peanut Agglutinin; 0 / Polyvinyls; 0 / poly(N-vinylacetamide); 0 / red fluorescent protein
  •  go-up   go-down


Advertisement
4. Bennani B, Gilles S, Fina F, Nanni I, Ibrahimi SA, Riffi AA, Nejjari C, Benajeh DA, El Abkari M, Martin PM, Ouafik L: Mutation analysis of BRAF exon 15 and KRAS codons 12 and 13 in Moroccan patients with colorectal cancer. Int J Biol Markers; 2010 Oct-Dec;25(4):179-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutation analysis of BRAF exon 15 and KRAS codons 12 and 13 in Moroccan patients with colorectal cancer.
  • We investigated the occurrence of BRAF exon 15 and KRAS codon 12 and 13 mutations in Moroccan patients with colorectal cancer.
  • METHODS: Sixty-two samples from patients with sporadic colorectal adenocarcinomas were studied for BRAF exon 15 and KRAS codon 12 and 13 mutations.
  • CONCLUSION: Despite the limited study sample, our data suggest that KRAS mutations arise more frequently than BRAF mutations in Moroccan patients with colorectal carcinomas.
  • The KRAS mutation status must be assessed in a large cohort of Moroccan patients to confirm these findings and to determine whether this mutation in combination with extrinsic, environmental or microenvironmental factors might be involved in the high frequency of colorectal cancer in middle-aged Moroccans.
  • [MeSH-major] Adenocarcinoma / genetics. Colorectal Neoplasms / genetics. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins B-raf / genetics. ras Proteins / genetics

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Biol Markers. 2011 Oct-Dec;26(4):276-7 [22139644.001]
  • (PMID = 21161938.001).
  • [ISSN] 1724-6008
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Codon; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras); EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


5. Wijsman JA, Obert LA, Paulissen J, Garrido R, Toy KA, Dunstan RW: A practical method to determine the amount of tissue to analyze using laser scanning cytometry. Cytometry A; 2007 Jul;71(7):501-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: This approach was used to evaluate the expression of immunohistochemical markers with differing tissue distributions in liver (PMP70, CYP1A2, and Ki67 positive macrophages) and a colorectal adenocarcinoma (activated caspase-3 positive cells), which exhibited diffuse, regional (centrilobular), random, and irregular distribution patterns respectively.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17366639.001).
  • [ISSN] 1552-4922
  • [Journal-full-title] Cytometry. Part A : the journal of the International Society for Analytical Cytology
  • [ISO-abbreviation] Cytometry A
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Biomarkers, Tumor
  •  go-up   go-down


6. Watanapokasin R, Jarinthanan F, Jerusalmi A, Suksamrarn S, Nakamura Y, Sukseree S, Uthaisang-Tanethpongtamb W, Ratananukul P, Sano T: Potential of xanthones from tropical fruit mangosteen as anti-cancer agents: caspase-dependent apoptosis induction in vitro and in mice. Appl Biochem Biotechnol; 2010 Oct;162(4):1080-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In vitro analysis with a human colorectal adenocarcinoma cell line, COLO 205, showed that mangosteen xanthones not only inhibit the proliferation of target cells but also induce their death by apoptosis that involves the activation of the caspase cascade.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / pharmacology. Apoptosis / drug effects. Caspases / metabolism. Colorectal Neoplasms / physiopathology. Garcinia mangostana / chemistry. Neoplasms / physiopathology. Plant Extracts / pharmacology. Xanthones / pharmacology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20101528.001).
  • [ISSN] 1559-0291
  • [Journal-full-title] Applied biochemistry and biotechnology
  • [ISO-abbreviation] Appl. Biochem. Biotechnol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Plant Extracts; 0 / Xanthones; EC 3.4.22.- / Caspases
  •  go-up   go-down


7. Gennatas C, Michalaki V, Gennatas S, Papalambros E: Irinotecan plus capecitabine as first-line chemotherapy in advanced colorectal cancer. Anticancer Res; 2008 May-Jun;28(3B):1923-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Irinotecan plus capecitabine as first-line chemotherapy in advanced colorectal cancer.
  • 5-FU/leucovorin in colorectal cancer treatment.
  • THE AIM of this study was to evaluate efficacy and safety of the combination chemotherapy of irinotecan plus capecitabine (XELIRI), in patients with advanced colorectal adenocarcinoma.
  • CONCLUSION: XELIRI is a well-tolerated regimen, with an activity comparable to, but more convenient than, irinotecan-5-FU i.v. combinations in patients with previously untreated advanced colorectal cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colorectal Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18630482.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; 7673326042 / irinotecan; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


8. Burnett BP, Jia Q, Zhao Y, Levy RM: A medicinal extract of Scutellaria baicalensis and Acacia catechu acts as a dual inhibitor of cyclooxygenase and 5-lipoxygenase to reduce inflammation. J Med Food; 2007 Sep;10(3):442-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Prostaglandin E2 generation was inhibited by the mixed extract in human osteosarcoma cells expressing COX-2, while leukotriene production was inhibited in both human cell lines, immortalized THP-1 monocyte and HT-29 colorectal adenocarcinoma.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17887937.001).
  • [ISSN] 1096-620X
  • [Journal-full-title] Journal of medicinal food
  • [ISO-abbreviation] J Med Food
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Cyclooxygenase Inhibitors; 0 / Enzyme Inhibitors; 0 / Flavonoids; 0 / Lipoxygenase Inhibitors; 0 / Plant Extracts; 347Q89U4M5 / baicalin; 8R1V1STN48 / Catechin; EC 1.14.99.1 / Cyclooxygenase 1; EC 1.14.99.1 / Cyclooxygenase 2; K7Q1JQR04M / Dinoprostone
  •  go-up   go-down


9. Jung JY, Song MH, Park YS, Jo YJ, Kim SH, Jun DW, Kim DH, Lee WM: [A case of mucinous noncystic carcinoma of the pancreas]. Korean J Gastroenterol; 2008 Mar;51(3):204-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is a well-defined entity in breast or large bowel.
  • In the past, MNCC generally had been categorized together with ordinary ductal adenocarcinoma or misdiagnosed as mucinous cystadenocarcinoma or signet-ring cell carcinoma.
  • The new WHO classification lists MNCC as a variant of ductal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Adult. Breast Neoplasms / diagnosis. Diagnosis, Differential. Female. Humans. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18451696.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


10. Zhang J, Ding Y, Zhou Z, Li H, Zhou B: [Expression of human papillomavirus 16 E7 DNA in patients with colorectal adenocarcinoma]. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2005 Oct;22(5):1024-6, 1044
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of human papillomavirus 16 E7 DNA in patients with colorectal adenocarcinoma].
  • The relationship between Human papillomavirus (HPV) 16 infection and the natural course of colorectal adenocarcinoma has not been fully defined.
  • In this study, the HPV 16 E7 DNA was detected in 82 patients with primary colorectal adenocarcinoma to study the relationship between HPV 16 infection and colorectal carcinoma.
  • Our results showed HPV16 E7 DNA expression was significantly higher in colorectal carcinoma (42/82) than in adjacent normal mucosa (4/82).
  • The correlation was found between HPV16 E7 expression and tumor's location; the positive rate was 18.18% in the ascending colon carcinoma group and 64.10% in the rectal carcinoma group.
  • These results indicated that there was correlation between colorectal adenocarcinoma and HPV 16 infection.
  • HPV16 infection was relatively higher in the colorectal carcinoma and rare in the adjacent normal mucosa.
  • [MeSH-major] Adenocarcinoma / virology. Colorectal Neoplasms / virology. Oncogene Proteins, Viral / biosynthesis. Papillomavirus Infections / virology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16294745.001).
  • [ISSN] 1001-5515
  • [Journal-full-title] Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi
  • [ISO-abbreviation] Sheng Wu Yi Xue Gong Cheng Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / Oncogene Proteins, Viral; 0 / Papillomavirus E7 Proteins; 0 / oncogene protein E7, Human papillomavirus type 16
  •  go-up   go-down


11. Kang WY, Chen WT, Wu MT, Chai CY: The expression of CD66a and possible roles in colorectal adenoma and adenocarcinoma. Int J Colorectal Dis; 2007 Aug;22(8):869-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The expression of CD66a and possible roles in colorectal adenoma and adenocarcinoma.
  • BACKGROUND: The aim of our study was to analyze the expression and possible role of CD66a in colorectal adenoma and adenocarcinoma and the relationship between its expression and pre-operation serum carcinoembryonic antigen (CEA) level and tumor stage in patients with colorectal adenocarcinomas.
  • METHODS: Paraffin-embedded sections from 184 patients including 42 colorectal adenomas with low-grade dysplasia, 43 adenomas with high-grade dysplasia, and 99 adenocarcinomas were collected for this study.
  • RESULTS: The expression of CD66a was found not only in the apical membrane of neoplastic glands but also in secretion within the lumen of the neoplastic glands including adenomas and adenocarcinomas.
  • Expressions of secreted CD66a were of higher level in adenocarcinoma than in adenoma with high-grade dysplasia and adenoma with low-grade dysplasia (p < 0.0001).
  • High expression of secreted CD66a was also associated with tumor stage, invasion, and pre-operation serum CEA level of patients with colorectal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / immunology. Adenoma / immunology. Antigens, CD / analysis. Cell Adhesion Molecules / analysis. Colorectal Neoplasms / immunology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1236-44 [10728682.001]
  • [Cites] Science. 1998 Sep 4;281(5382):1509-12 [9727977.001]
  • [Cites] J Histochem Cytochem. 1988 Jul;36(7):729-39 [3290331.001]
  • [Cites] J Cell Sci. 2002 Mar 15;115(Pt 6):1273-84 [11884526.001]
  • [Cites] Cancer Gene Ther. 1999 Jul-Aug;6(4):313-21 [10419049.001]
  • [Cites] J Cell Biol. 1992 Jul;118(2):457-66 [1378450.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Nov 15;90(22):10744-8 [7504281.001]
  • [Cites] Biochem Biophys Res Commun. 1996 Oct 23;227(3):775-81 [8886009.001]
  • [Cites] Am J Pathol. 1993 Jul;143(1):250-7 [8317550.001]
  • [Cites] Hum Pathol. 1994 Sep;25(9):849-56 [8088758.001]
  • [Cites] J Biol Chem. 2000 Jun 9;275(23):17894-9 [10749878.001]
  • [Cites] Eur J Biochem. 1993 May 1;213(3):1109-16 [8504806.001]
  • [Cites] J Histochem Cytochem. 1996 Jan;44(1):35-41 [8543780.001]
  • [Cites] J Immunol. 1993 Jun 1;150(11):4978-84 [8496599.001]
  • [Cites] Br J Cancer. 1998 May;77(10):1661-8 [9635845.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Sep;85(18):6959-63 [2457922.001]
  • [Cites] Am J Pathol. 1998 Jun;152(6):1401-6 [9626043.001]
  • [Cites] Mol Immunol. 1979 Apr;16(4):245-52 [91094.001]
  • [Cites] J Histochem Cytochem. 1997 Jul;45(7):957-63 [9212821.001]
  • (PMID = 17143599.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CD66 antigens; 0 / CTNNB1 protein, human; 0 / Carcinoembryonic Antigen; 0 / Cell Adhesion Molecules; 0 / beta Catenin
  •  go-up   go-down


12. Georgescu SO, Neacşu CN, Vintilă D, Popa P, Forţu L, Nistor A, Ferariu D, Târcoveanu E: [Long-term results after surgery for colorectal adenocarcinoma, stage I-III. Problems of prognosis]. Rev Med Chir Soc Med Nat Iasi; 2007 Oct-Dec;111(4):932-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term results after surgery for colorectal adenocarcinoma, stage I-III. Problems of prognosis].
  • [Transliterated title] Rezultate la distanţă după tratamentul chirurgical al adenocarcinomului colo-rectal stadiile I-III. Probleme de prognostic.
  • Colorectal cancer is one of the leading causes of cancer-related death worldwide.
  • STUDY DESIGN: Prospective study on 142 consecutively cases with stage I to III colorectal adenocarcinomas (TNM AJCC/UICC) in which patients underwent potentially curative surgery in one single public health service (1st Surgical Clinic Iaşi, Romania) between 2004 and 2005.
  • The surgical procedures performed were the following: right colectomy (n = 54; 30%); transverse colectomy (n = 2; 1.4%); left colectomy (n = 19; 13.4%); segmental colon resection with anastomosis (n = 5 ; 3.5%); Hartmann procedure (n = 18; 12.7%); anterior rectal resection (n = 11; 7.7%) and abdominoperineal resection (n = 33; 23.2%).
  • RESULTS: The factors with a significant negative influence in overall survival and 42-months survival rates were: the age over 70 years, the emergency surgery related to cancer's complications, the advanced AJCC/ UICC stage, vascular invasion, perineural invasion, the recurrence of disease, the moderate and lower differentiated adenocarcinoma and incomplete or not performed chemotherapy.
  • CONCLUSION: Even with a radical surgical approach the advanced stage of colorectal adenocarcinoma has a low prognostic, but some other factors have also a high significance in postoperative outcome.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Colectomy / methods. Colorectal Neoplasms / pathology. Colorectal Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18389783.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


13. Nielsen CK, Campbell JI, Ohd JF, Mörgelin M, Riesbeck K, Landberg G, Sjölander A: A novel localization of the G-protein-coupled CysLT1 receptor in the nucleus of colorectal adenocarcinoma cells. Cancer Res; 2005 Feb 1;65(3):732-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel localization of the G-protein-coupled CysLT1 receptor in the nucleus of colorectal adenocarcinoma cells.
  • Searching for a link between inflammation and colon cancer, we have found that the inflammatory mediator leukotriene D(4) (LTD(4)), via its receptor CysLT(1), induces cyclooxygenase-2 expression, survival, and proliferation in intestinal epithelial cells.
  • In conjunction with our previous observation that CysLT(1) receptor expression is increased in colorectal adenocarcinomas, we here found an increased nuclear localization of the CysLT(1) receptor in colorectal adenocarcinomas.
  • It was found to be located in the outer nuclear membrane in colon cancer cells and in the nontransformed epithelial cell line Int 407 cells by Western blot and electron microscopy.
  • The significance of these experimental findings is supported by the observed correlation between the proliferative marker Ki-67 and nuclear CysLT(1) receptor localization in colorectal adenocarcinomas.
  • The present findings indicate that LTD(4) cannot only be synthesized but also signal proliferation through nuclear CysLT(1) receptors, stressing the importance of leukotrienes in inflammation-induced colon carcinogenesis.
  • [MeSH-major] Adenocarcinoma / metabolism. Colorectal Neoplasms / metabolism. Membrane Proteins / metabolism. Nuclear Localization Signals / metabolism. Receptors, Leukotriene / metabolism


14. Pachon G, Rasoanaivo H, Azqueta A, Rakotozafy JC, Raharisololalao A, De Cerain AL, De Lapuente J, Borràs M, Moukha S, Centelles JJ, Creppy EE, Cascante M: Anticancer effect of a new benzophenanthridine isolated from Zanthoxylum madagascariense (Rutaceline). In Vivo; 2007 Mar-Apr;21(2):417-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Rutaceline was evaluated for its antiproliferative capacity on the human colorectal adenocarcinoma (Caco-2) and the African green monkey kidney (Vero) cell lines.
  • 220 microM) indicating a higher cell growth inhibitory effect on the colon adenocarcinoma cells.
  • [MeSH-minor] Adenocarcinoma. Animals. Cell Line. Cell Line, Tumor. Cercopithecus aethiops. Colorectal Neoplasms. Humans. Kidney / drug effects. Kinetics. Madagascar. Vero Cells

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17436597.001).
  • [ISSN] 0258-851X
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzophenanthridines
  •  go-up   go-down


15. Nakayama T, Hatachi G, Wen CY, Yoshizaki A, Yamazumi K, Niino D, Sekine I: Expression and significance of Tie-1 and Tie-2 receptors, and angiopoietins-1, 2 and 4 in colorectal adenocarcinoma: Immunohistochemical analysis and correlation with clinicopathological factors. World J Gastroenterol; 2005 Feb 21;11(7):964-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and significance of Tie-1 and Tie-2 receptors, and angiopoietins-1, 2 and 4 in colorectal adenocarcinoma: Immunohistochemical analysis and correlation with clinicopathological factors.
  • The objective of this study was to establish a comprehensive Tie-1 and Tie-2 and Ang-1, 2 and 4 expression profile in human colorectal adenocarcinomas.
  • METHODS: We examined 96 cases of surgically resected human colorectal adenocarcinoma by immunohistochemistry and investigated the statistical correlation between the expressions of Ties and Angs and clinicopathological factors.
  • RESULTS: Among the 96 cases of adenocarcinoma, 87 (90.6%), 92 (95.8%), 83 (86.5%), 89 (92.7%), and 76 cases (79.2%) showed positive staining in the cytoplasm of carcinoma cells for the Tie-1 and Tie-2 and Ang-1, 2 and 4 proteins, respectively.
  • Ties and Angs were highly expressed in human colorectal adenocarcinoma cells.
  • CONCLUSION: These findings suggest that the Tie-Ang receptor-ligand complex is one of the factors involved in the cellular differentiation and progression of human colorectal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Angiopoietin-1 / metabolism. Angiopoietin-2 / metabolism. Colorectal Neoplasms / metabolism. Receptor, TIE-1 / metabolism. Receptor, TIE-2 / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15742397.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / ANGPT1 protein, human; 0 / Angiopoietin-1; 0 / Angiopoietin-2; 0 / Angiopoietins; 0 / Ligands; 0 / angiopoietin 4; EC 2.7.10.1 / Receptor, TIE-1; EC 2.7.10.1 / Receptor, TIE-2
  • [Other-IDs] NLM/ PMC4250786
  •  go-up   go-down


16. Dakouras A, Nikiteas N, Papadakis E, Perakis M, Valis D, Rallis G, Tzanakis N, Peros G, Tsigkris C, Kittas C, Karakitsos P: P53Arg72 homozygosity and its increased incidence in left-sided sporadic colorectal adenocarcinomas, in a Greek-Caucasian population. Anticancer Res; 2008 Mar-Apr;28(2A):1039-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] P53Arg72 homozygosity and its increased incidence in left-sided sporadic colorectal adenocarcinomas, in a Greek-Caucasian population.
  • BACKGROUND: The current case-control study was conducted in order to elucidate any possible association of the single nucleotide polymorphism (SNP) of codon 72 of the p53 gene (Arg72Pro) and sporadic colorectal adenocarcinoma development in a Caucasian population in Greece.
  • MATERIALS AND METHODS: Genomic DNA samples from 93 sporadic colorectal adenocarcinoma cases and 95 healthy controls (age and ethnicity matched) were used to genotype the p53 codon 72 polymorphism.
  • RESULTS: A strong association of the homozygous 72Arg allele with the development of colorectal cancer was observed (Chi-Square = 11,212, p = 0.001, O.R = 2.902, 95% (CI) = 1.540-5.469, for Arg/Arg vs. Arg/Pro and Pro/Pro).
  • When tumor location was accounted for, the Arg/Arg carrier genotypes were associated with an increased incidence of left colon cancer (Chi-Square = 5.256, p = 0.026, OR = 2.975, 95% (CI) = 1.150-7.699).
  • CONCLUSION: p53Arg homozygosity is associated with the development of sporadic colorectal adenocarcinoma, in the Greek-Caucasian population studied and this polymorphism may have a significant prognostic value, where tumor location is concerned.
  • [MeSH-major] Adenocarcinoma / genetics. Colorectal Neoplasms / genetics. Genes, p53

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. (L)-ARGININE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18507052.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 94ZLA3W45F / Arginine
  •  go-up   go-down


17. Martínez JG, Pérez-Escuredo J, López F, Suárez C, Alvarez-Marcos C, Llorente JL, Hermsen MA: Microsatellite instability analysis of sinonasal carcinomas. Otolaryngol Head Neck Surg; 2009 Jan;140(1):55-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Intestinal-type sinonasal adenocarcinoma (ITAC) and squamous cell carcinoma of the nasal cavity (SCCNC) are histopathologically but not etiologically similar to colorectal adenocarcinoma or to laryngeal squamous cell carcinoma, respectively.
  • CONCLUSION: MSI may be involved in squamous cell carcinoma, but not in adenocarcinoma of the nasal cavities.
  • [MeSH-major] Adenocarcinoma / genetics. Carcinoma, Squamous Cell / genetics. Microsatellite Instability. Nose Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19130962.001).
  • [ISSN] 0194-5998
  • [Journal-full-title] Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
  • [ISO-abbreviation] Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


18. Soares MI, Brito AF, Laranjo M, Abrantes AM, Botelho MF, Paixão JA, Beja AM, Silva MR, Pinho E Melo TM: Chiral 6-hydroxymethyl-1H,3H-pyrrolo[1,2-c]thiazoles: novel antitumor DNA monoalkylating agents. Eur J Med Chem; 2010 Oct;45(10):4676-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • New chiral 1H,3H-pyrrolo[1,2-c]thiazoles were synthesized and screened for their in vitro activity as anti-cancer agents in three human tumor cell lines, colorectal adenocarcinoma, melanoma and breast adenocarcinoma. (R)-6-Hydroxymethyl-5-methyl-3-phenyl-1H,3H-pyrrolo[1,2-c]thiazole and the corresponding benzylcarbamate showed selectivity for breast cancer cell lines with IC(50) values of 2.4 microM and 2.2 microM, respectively.
  • The latter also showed significant activity against colorectal adenocarcinoma cancer cell lines (IC(50) = 8.7 microM).
  • [MeSH-minor] Adenocarcinoma / drug therapy. Breast Neoplasms / drug therapy. Cell Line, Tumor. Colorectal Neoplasms / drug therapy. Drug Screening Assays, Antitumor. Female. Humans. Melanoma / drug therapy

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20705366.001).
  • [ISSN] 1768-3254
  • [Journal-full-title] European journal of medicinal chemistry
  • [ISO-abbreviation] Eur J Med Chem
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Pyrroles; 0 / Thiazoles; 9007-49-2 / DNA
  •  go-up   go-down


19. Rondonotti E, Pennazio M, Toth E, Menchen P, Riccioni ME, De Palma GD, Scotto F, De Looze D, Pachofsky T, Tacheci I, Havelund T, Couto G, Trifan A, Kofokotsios A, Cannizzaro R, Perez-Quadrado E, de Franchis R, European Capsule Endoscopy Group, Italian Club for Capsule Endoscopy (CICE), Iberian Group for Capsule Endoscopy: Small-bowel neoplasms in patients undergoing video capsule endoscopy: a multicenter European study. Endoscopy; 2008 Jun;40(6):488-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small-bowel neoplasms in patients undergoing video capsule endoscopy: a multicenter European study.
  • BACKGROUND AND STUDY AIM: Small-bowel tumors account for 1% - 3% of all gastrointestinal neoplasms.
  • The aim of the study was to evaluate the frequency, clinical presentation, diagnostic/therapeutic work-up, and endoscopic appearance of small-bowel tumors in a large population of patients undergoing VCE.
  • PATIENTS AND METHODS: Identification by a questionnaire of patients with VCE findings suggesting small-bowel tumors and histological confirmation of the neoplasm seen in 29 centers of 10 European Countries.
  • RESULTS: Of 5129 patients undergoing VCE, 124 (2.4%) had small-bowel tumors (112 primary, 12 metastatic).
  • The main primary small-bowel tumor type was gastrointestinal stromal tumor (GIST) (32%) followed by adenocarcinoma (20%) and carcinoid (15%); 66% of secondary small-bowel tumors were melanomas.
  • Retention of the capsule occurred in 9.8% of patients with small-bowel tumors.
  • CONCLUSIONS: Our data suggest that VCE detects small-bowel tumors in a small proportion of patients undergoing this examination, but the early use of this tool can shorten the diagnostic work-up and influence the subsequent management of these patients.
  • [MeSH-major] Capsule Endoscopy / methods. Intestinal Neoplasms / diagnosis. Intestinal Neoplasms / epidemiology. Intestine, Small / pathology
  • [MeSH-minor] Adult. Age Distribution. Aged. Biopsy, Needle. Early Diagnosis. Europe / epidemiology. Female. Humans. Incidence. Male. Middle Aged. Multicenter Studies as Topic. Neoplasm Staging. Normal Distribution. Probability. Risk Assessment. Sensitivity and Specificity. Sex Distribution. Statistics, Nonparametric

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18464193.001).
  • [ISSN] 1438-8812
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Investigator] Marmo R; Pezzoli A; Girelli CM; Opezzi M; De Luca L; Pantanella P; Alberani A; Chiaverini R; Gonzalez Suarez B; Fernandez Diez S; Fernandez Urien I; Valle J; Cabriada J
  •  go-up   go-down


20. Lee YY, Yu CP, Lin CK, Nieh S, Hsu KF, Chiang H, Jin JS: Expression of survivin and cortactin in colorectal adenocarcinoma: association with clinicopathological parameters. Dis Markers; 2009;26(1):9-18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of survivin and cortactin in colorectal adenocarcinoma: association with clinicopathological parameters.
  • We tested the hypothesis that survivin and cortactin expressions correlate with the clinico-pathological parameters of colorectal adenocarcinomas and survival time.
  • METHODS: Immunohistochemical analysis of survivin and cortactin were performed using tissue microarrays of 119 specimens from 18 well, 50 moderately, and 27 poorly differentiated colorectal adenocarcinomas and 24 colorectal adenomas with dysplasia.
  • As control, 10 specimens of normal colorectal epithelia were included.
  • RESULTS: The percentage of cells immunostained and the immunostaining scores for survivin and cortactin were all significantly higher in well-, moderately, and poorly differentiated colorectal adenocarcinomas than in normal colorectal epithelia.
  • Survivin and cortactin may be good biomarkers of aggressiveness of colorectal adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Colorectal Neoplasms / metabolism. Cortactin / metabolism. Microtubule-Associated Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19242064.001).
  • [ISSN] 0278-0240
  • [Journal-full-title] Disease markers
  • [ISO-abbreviation] Dis. Markers
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Biomarkers, Tumor; 0 / CTTN protein, human; 0 / Cortactin; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins
  • [Other-IDs] NLM/ PMC3833605
  •  go-up   go-down


21. Meng F, Cai X, Duan J, Matteucci MG, Hart CP: A novel class of tubulin inhibitors that exhibit potent antiproliferation and in vitro vessel-disrupting activity. Cancer Chemother Pharmacol; 2008 May;61(6):953-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Three lead compounds, TH-337, TH-482 and TH-494, exhibit potent antiproliferative activity against cell lines derived from human pancreatic carcinoma, human breast adenocarcinoma and human colorectal adenocarcinoma cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17639393.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / ABCG2 protein, human; 0 / ATP Binding Cassette Transporter, Sub-Family G, Member 2; 0 / ATP-Binding Cassette Transporters; 0 / ATP-Binding Cassette, Sub-Family B, Member 1; 0 / Angiogenesis Inhibitors; 0 / Fluoresceins; 0 / Fluorescent Dyes; 0 / Multidrug Resistance-Associated Proteins; 0 / Neoplasm Proteins; 0 / Tubulin; 0 / Tubulin Modulators; 148504-34-1 / calcein AM; EC 5.99.1.3 / DNA Topoisomerases, Type II; Y49M64GZ4Q / multidrug resistance-associated protein 1
  •  go-up   go-down


22. Yoo PS, Sullivan CA, Kiang S, Gao W, Uchio EM, Chung GG, Cha CH: Tissue microarray analysis of 560 patients with colorectal adenocarcinoma: high expression of HuR predicts poor survival. Ann Surg Oncol; 2009 Jan;16(1):200-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tissue microarray analysis of 560 patients with colorectal adenocarcinoma: high expression of HuR predicts poor survival.
  • The purpose of this study is to characterize the expression of HuR in colorectal carcinoma and determine its correlation with clinical outcome.
  • A tissue microarray consisting of tumors from 560 patients with colorectal adenocarcinoma was analyzed for HuR protein expression using a quantitative, automated immunofluorescent microscopy system (AQUA).
  • We conclude that expression of high levels of HuR correlates with features of advanced disease and portends poorer survival in patients with colorectal adenocarcinoma.
  • These results further suggest that HuR exerts its tumorigenic effects through VEGF-mediated angiogenesis and may be a novel therapeutic target in colorectal cancer.
  • [MeSH-major] Adenocarcinoma / metabolism. Antigens, Surface / metabolism. Biomarkers, Tumor / metabolism. Colorectal Neoplasms / metabolism. RNA-Binding Proteins / metabolism. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19009247.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / Antigens, Surface; 0 / Biomarkers, Tumor; 0 / ELAV Proteins; 0 / ELAV-Like Protein 1; 0 / ELAVL1 protein, human; 0 / RNA-Binding Proteins; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


23. Bazan V, Agnese V, Corsale S, Calò V, Valerio MR, Latteri MA, Vieni S, Grassi N, Cicero G, Dardanoni G, Tomasino RM, Colucci G, Gebbia N, Russo A, Gruppo Oncologico dell'Italia Meridionale (GOIM): Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: results of a 5-year Gruppo Oncologico dell'Italia Meridionale (GOIM) prospective study. Ann Oncol; 2005 May;16 Suppl 4:iv50-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: results of a 5-year Gruppo Oncologico dell'Italia Meridionale (GOIM) prospective study.
  • BACKGROUND: Although Ki-ras and TP53 mutations have probably been the genetic abnormalities most exhaustively implicated and studied in colorectal cancer (CRC) progression, their significance in terms of disease relapse and overall survival has not yet clearly been established.
  • PATIENTS AND METHODS: A prospective study was carried out on paired tumor and normal colon tissue samples from a consecutive series of 160 previously-untreated patients, undergoing resective surgery for primary operable sporadic CRC.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15923430.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; 2880D3468G / Levamisole; EC 3.6.5.2 / ras Proteins; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


24. Cartwright T, Kuefler P, Cohn A, Hyman W, Berger M, Richards D, Vukelja S, Nugent JE, Ruxer RL Jr, Boehm KA, Asmar L: Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancer. Clin Colorectal Cancer; 2008 Nov;7(6):390-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancer.
  • BACKGROUND: XELIRI (capecitabine/irinotecan) is effective and well tolerated in metastatic colorectal cancer (mCRC).
  • PATIENTS AND METHODS: Subjects had histologically confirmed unresectable colorectal adenocarcinoma (with T4 lesions) after preoperative chemoradiation and/or metastases.
  • RESULTS: Baseline characteristics (N = 70): 43 men (61%); median age, 61.5 years; Eastern Cooperative Oncology Group performance status 0/1 = 66%/34%; 94% adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Colorectal Neoplasms / drug therapy. Deoxycytidine / analogs & derivatives. Fluorouracil / analogs & derivatives

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CETUXIMAB .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19036692.001).
  • [ISSN] 1533-0028
  • [Journal-full-title] Clinical colorectal cancer
  • [ISO-abbreviation] Clin Colorectal Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; 7673326042 / irinotecan; PQX0D8J21J / Cetuximab; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


25. Goh V, Halligan S, Daley F, Wellsted DM, Guenther T, Bartram CI: Colorectal tumor vascularity: quantitative assessment with multidetector CT--do tumor perfusion measurements reflect angiogenesis? Radiology; 2008 Nov;249(2):510-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colorectal tumor vascularity: quantitative assessment with multidetector CT--do tumor perfusion measurements reflect angiogenesis?
  • PURPOSE: To establish the relationships between quantitative perfusion computed tomography (CT) parameters-specifically, primary tumor blood flow, blood volume, transit time, and permeability surface-area product-and immunohistologic markers of angiogenesis in colorectal cancer.
  • MATERIALS AND METHODS: After institutional review board approval and informed patient consent were obtained for this prospective study, 23 patients (11 men, 12 women; mean age, 68.4 years; age range, 34.8-87.1 years) with colorectal adenocarcinoma underwent a 65-second perfusion CT examination, and tumor blood flow, blood volume, mean transit time, and permeability surface-area product were determined.
  • CONCLUSION: Tumor permeability surface-area product and blood volume correlate positively with MVD and may reflect the microvascularity of colorectal tumors.
  • [MeSH-major] Adenocarcinoma / radiography. Colorectal Neoplasms / radiography. Neovascularization, Pathologic / radiography. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) RSNA, 2008.
  • (PMID = 18812560.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Contrast Media; 0 / Glucose Transporter Type 1; 0 / Vascular Endothelial Growth Factor A; JR13W81H44 / Iopamidol
  •  go-up   go-down


26. Sierko E, Tokajuk P, Butkiewicz A, Sulkowski S, Zimnoch L, Wojtukiewicz MZ: [Expression evaluation of in loco coagulation system in colorectal cancer]. Pol Merkur Lekarski; 2005 Feb;18(104):176-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression evaluation of in loco coagulation system in colorectal cancer].
  • Colorectal cancer is the third most often cause of morbidity and mortality due to cancer in Poland.
  • 21 cases of G2 colorectal adenocarcinoma obtained during surgical resection were examined.
  • The results indicate extravascular activation of blood coagulation in loco in colorectal cancer that is TF-dependent.
  • [MeSH-major] Blood Coagulation. Blood Coagulation Factors / metabolism. Carcinoma / metabolism. Colorectal Neoplasms / metabolism

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17877125.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Blood Coagulation Factors; 9001-25-6 / Factor VII; 9001-26-7 / Prothrombin; 9001-29-0 / Factor X; 9001-31-4 / Fibrin; 9001-32-5 / Fibrinogen; 9035-58-9 / Thromboplastin; EC 3.4.21.22 / Factor IXa
  •  go-up   go-down


27. Holten-Andersen MN, Hansen U, Brünner N, Nielsen HJ, Illemann M, Nielsen BS: Localization of tissue inhibitor of metalloproteinases 1 (TIMP-1) in human colorectal adenoma and adenocarcinoma. Int J Cancer; 2005 Jan 10;113(2):198-206
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localization of tissue inhibitor of metalloproteinases 1 (TIMP-1) in human colorectal adenoma and adenocarcinoma.
  • We have previously demonstrated that TIMP-1 is elevated in blood from colorectal cancer patients and that high TIMP-1 levels predict poor prognosis.
  • To clarify the role of TIMP-1 in colorectal tumorigenesis, the expression pattern of TIMP-1 in benign and malignant colorectal tumors was studied.
  • In all of 24 cases of colorectal adenocarcinoma TIMP-1 mRNA was detected by in situ hybridization.
  • In conclusion, TIMP-1 expression is a rare event in benign human colon tissue but is highly expressed by myofibroblasts in association with invading colon cancer cells.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Adenoma / genetics. Adenoma / pathology. Colorectal Neoplasms / genetics. Colorectal Neoplasms / pathology. Tissue Inhibitor of Metalloproteinase-1 / biosynthesis. Tissue Inhibitor of Metalloproteinase-1 / pharmacology
  • [MeSH-minor] Case-Control Studies. Cell Transformation, Neoplastic. Diagnosis, Differential. Fibroblasts / physiology. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Neoplasm Invasiveness. RNA, Messenger / analysis. RNA, Messenger / biosynthesis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15386409.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Tissue Inhibitor of Metalloproteinase-1
  •  go-up   go-down


28. Avinash SS, Anitha M, Vinodchandran, Rao GM, Sudha K, Shetty BV: Advanced oxidation protein products and total antioxidant activity in colorectal carcinoma. Indian J Physiol Pharmacol; 2009 Oct-Dec;53(4):370-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced oxidation protein products and total antioxidant activity in colorectal carcinoma.
  • The present study was designed to assess the levels of advanced oxidation protein products (AOPP) and percent hemolysis (that indirectly indicates the degree of membrane damage secondary to lipid peroxidation) in colorectal carcinoma.
  • Investigations were conducted in 45 cases of recently diagnosed primary colorectal adenocarcinoma.
  • We observed a very high significant increase (P<0.001) in AOPP, percent hemolysis and a highly significant increase (P<0.01) in globulin in colorectal carcinoma.
  • We observed a very high significant decrease (P<0.001) in whole blood GSH, total thiols, albumin, AOA and a significant decrease (P<0.05) in plasma GSH in colorectal carcinoma.
  • A very high significant negative correlation between percent hemolysis and AOA and an apparent negative correlation between total thiols and AOPP was seen in colorectal carcinoma.
  • This demonstrated oxidative stress, decreased antioxidant status and secondary inflammatory response in colorectal carcinoma.
  • [MeSH-major] Antioxidants / metabolism. Blood Proteins / metabolism. Colorectal Neoplasms / blood

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20509331.001).
  • [ISSN] 0019-5499
  • [Journal-full-title] Indian journal of physiology and pharmacology
  • [ISO-abbreviation] Indian J. Physiol. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Blood Proteins; 0 / Globulins; 0 / Serum Albumin; 0 / Sulfhydryl Compounds; GAN16C9B8O / Glutathione
  •  go-up   go-down


29. de Noo ME, Tollenaar RA, Deelder AM, Bouwman LH: Current status and prospects of clinical proteomics studies on detection of colorectal cancer: hopes and fears. World J Gastroenterol; 2006 Nov 7;12(41):6594-601
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current status and prospects of clinical proteomics studies on detection of colorectal cancer: hopes and fears.
  • Colorectal adenocarcinoma (CRC) is the third most common type of cancer and the fourth most frequent cause of death due to cancer worldwide.
  • Given the natural history of CRC, early diagnosis appears to be the most appropriate tool to reduce disease-related mortality.
  • This paper focuses on the current status of clinical proteomics research in oncology and in colorectal cancer especially, and will reflect on pitfalls and fears in this relatively new area of clinical medicine, which are reproducibility issues and pre-analytical factors, statistical issues, and identification and nature of discriminating proteins/peptides.
  • [MeSH-major] Adenocarcinoma / diagnosis. Colorectal Neoplasms / diagnosis. Proteomics / methods

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 2002 Dec;126(12):1518-26 [12456215.001]
  • [Cites] Proteomics. 2003 Jan;3(1):56-63 [12548634.001]
  • [Cites] Clin Chem. 2006 Jun;52(6):1045-53 [16574760.001]
  • [Cites] Semin Oncol. 2005 Feb;32(1):24-34 [15726503.001]
  • [Cites] Nature. 2003 Mar 13;422(6928):233-7 [12634797.001]
  • [Cites] J Natl Cancer Inst. 2003 Mar 19;95(6):489-90; author reply 490-1 [12644546.001]
  • [Cites] Eur J Cancer. 2003 Apr;39(6):718-27 [12651195.001]
  • [Cites] Nat Rev Cancer. 2003 Apr;3(4):243-52 [12671663.001]
  • [Cites] Nat Rev Cancer. 2003 Apr;3(4):267-75 [12671665.001]
  • [Cites] J Am Coll Surg. 2003 May;196(5):722-8 [12742204.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2002 Oct;7(4):433-40 [12882527.001]
  • [Cites] Bioinformatics. 2003 Aug 12;19(12):1484-91 [12912828.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2904-11 [12912935.001]
  • [Cites] Gastroenterology. 2003 Feb;124(2):544-60 [12557158.001]
  • [Cites] Trends Biotechnol. 2002 Dec;20(12 Suppl):S30-4 [12570157.001]
  • [Cites] Technol Cancer Res Treat. 2002 Aug;1(4):297-304 [12625789.001]
  • [Cites] Anal Chem. 2005 Nov 15;77(22):7232-41 [16285670.001]
  • [Cites] Clin Chem. 2005 Dec;51(12):2229-35 [16223889.001]
  • [Cites] Nat Rev Cancer. 2005 Nov;5(11):845-56 [16239904.001]
  • [Cites] J Clin Invest. 2006 Jan;116(1):26-30 [16395400.001]
  • [Cites] J Clin Invest. 2006 Jan;116(1):271-84 [16395409.001]
  • [Cites] J Pathol. 2006 Apr;208(5):595-606 [16518808.001]
  • [Cites] Proteomics. 2006 Apr;6(7):2095-100 [16502467.001]
  • [Cites] World J Gastroenterol. 2006 Mar 14;12(10):1536-44 [16570345.001]
  • [Cites] Eur J Cancer. 2006 May;42(8):1068-76 [16603345.001]
  • [Cites] Biostatistics. 2003 Jul;4(3):449-63 [12925511.001]
  • [Cites] Lancet. 2003 Aug 9;362(9382):433-9 [12927430.001]
  • [Cites] J Proteome Res. 2003 Jul-Aug;2(4):361-72 [12938926.001]
  • [Cites] Proteomics. 2003 Sep;3(9):1667-72 [12973722.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6105-9 [14559785.001]
  • [Cites] BMC Bioinformatics. 2003 Jun 9;4:24 [12795817.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 3;96(5):353-6 [14996856.001]
  • [Cites] Anal Chem. 2004 Mar 15;76(6):1560-70 [15018552.001]
  • [Cites] Bioinformatics. 2004 Mar 22;20(5):777-85 [14751995.001]
  • [Cites] Nat Rev Cancer. 2004 Apr;4(4):309-14 [15057290.001]
  • [Cites] Gastroenterology. 2004 May;126(5):1448-53 [15131804.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2375-82 [15175439.001]
  • [Cites] World J Gastroenterol. 2004 Nov 1;10(21):3127-31 [15457557.001]
  • [Cites] Ann Intern Med. 1997 May 15;126(10):811-22 [9148658.001]
  • [Cites] Eur J Cancer. 2004 Nov;40(17):2613-22 [15541962.001]
  • [Cites] Ann Oncol. 2005 Jan;16(1):16-22 [15598930.001]
  • [Cites] J Clin Oncol. 2005 Jan 10;23(2):378-91 [15637400.001]
  • [Cites] Lancet. 2005 Jan 8-14;365(9454):153-65 [15639298.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):963-5 [15709159.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1110-8 [15709178.001]
  • [Cites] Nat Biotechnol. 2005 Mar;23(3):291-2 [15765078.001]
  • [Cites] BMC Bioinformatics. 2005;6:68 [15788095.001]
  • [Cites] Brief Funct Genomic Proteomic. 2005 Feb;3(4):322-31 [15814023.001]
  • [Cites] Clin Sci (Lond). 2005 May;108(5):369-83 [15831087.001]
  • [Cites] Gastroenterology. 2005 May;128(6):1685-95 [15887159.001]
  • [Cites] Clin Chem. 2005 Jun;51(6):973-80 [15845803.001]
  • [Cites] Am J Gastroenterol. 2005 Jun;100(6):1393-403 [15929776.001]
  • [Cites] Rapid Commun Mass Spectrom. 2005;19(12):1624-36 [15915451.001]
  • [Cites] J Proteome Res. 2005 May-Jun;4(3):972-81 [15952745.001]
  • [Cites] Anal Chem. 2005 Aug 15;77(16):5114-23 [16097747.001]
  • [Cites] Dig Surg. 2005;22(4):276-81 [16174984.001]
  • [Cites] Adv Exp Med Biol. 2000;477:349-78 [10849763.001]
  • [Cites] J Pathol. 2000 Nov;192(3):280-8 [11054709.001]
  • [Cites] Lancet. 2002 Feb 16;359(9306):572-7 [11867112.001]
  • [Cites] Gastrointest Endosc Clin N Am. 2002 Jan;12(1):53-63 [11916161.001]
  • [Cites] Eur J Cancer. 2002 May;38(7):872-9 [11978511.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3609-14 [12097261.001]
  • [Cites] Ann Intern Med. 2002 Jul 16;137(2):132-41 [12118972.001]
  • [Cites] Lancet. 2002 Jul 13;360(9327):170; author reply 170-1 [12126845.001]
  • [Cites] Clin Chem. 2002 Aug;48(8):1160-9 [12142368.001]
  • (PMID = 17075970.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 69
  • [Other-IDs] NLM/ PMC4125662
  •  go-up   go-down


30. Mumtaz M, Wågsäter D, Löfgren S, Hugander A, Zar N, Dimberg J: Decreased expression of the chemokine CCL21 in human colorectal adenocarcinomas. Oncol Rep; 2009 Jan;21(1):153-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased expression of the chemokine CCL21 in human colorectal adenocarcinomas.
  • To gain insight into the possible influence of CCL21 on colorectal cancer (CRC) we determined whether the CCL21 is altered in CRC tissue.
  • Patients with a tumour localized in the rectum revealed significantly lower level of CCL21 than patients with a tumour localized in the colon both compared with paired normal tissue.
  • Our study implied that lower level of CCL21 in CRC tissue supports the idea that cancer is related to immunodeficiency probably depending on regulatory factors produced by tumour cells and that the different levels of CCL21 in rectum and colon may reflect divergent mechanisms in colorectal carcinogenesis.
  • [MeSH-major] Adenocarcinoma / metabolism. Chemokine CCL21 / biosynthesis. Chemokine CCL21 / genetics. Colorectal Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19082456.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Chemokine CCL21
  •  go-up   go-down


31. Cleven AH, van Engeland M, Wouters BG, de Bruïne AP: Stromal expression of hypoxia regulated proteins is an adverse prognostic factor in colorectal carcinomas. Cell Oncol; 2007;29(3):229-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stromal expression of hypoxia regulated proteins is an adverse prognostic factor in colorectal carcinomas.
  • However, the expression and influence of hypoxia-regulated proteins on tumor biology are not well characterized in colorectal tumors.
  • We studied the role of protein expression of hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, carbonic anhydrase 9 (CA9) and glucose transporter 1 (GLUT1) in patients with colorectal adenocarcinomas.
  • METHODS: Expression of HIF-1alpha, HIF-2alpha, CA9 and GLUT1 was quantified by immunohistochemistry in 133 colorectal adenocarcinomas.
  • CONCLUSION: These observations show, that expression of hypoxia regulated proteins in tumor-associated stromal cells, as opposed to their expression in epithelial tumor cells, is associated with poor outcome in colorectal cancer.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Basic Helix-Loop-Helix Transcription Factors / metabolism. Carbonic Anhydrases / metabolism. Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / metabolism. Glucose Transporter Type 1 / metabolism. Hypoxia-Inducible Factor 1, alpha Subunit / metabolism. Stromal Cells / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17452775.001).
  • [ISSN] 1570-5870
  • [Journal-full-title] Cellular oncology : the official journal of the International Society for Cellular Oncology
  • [ISO-abbreviation] Cell. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Biomarkers, Tumor; 0 / Glucose Transporter Type 1; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / endothelial PAS domain-containing protein 1; EC 4.2.1.1 / CA9 protein, human; EC 4.2.1.1 / Carbonic Anhydrases
  • [Other-IDs] NLM/ PMC4617795
  •  go-up   go-down


32. Simiantonaki N, Taxeidis M, Jayasinghe C, Kurzik-Dumke U, Kirkpatrick CJ: Hypoxia-inducible factor 1 alpha expression increases during colorectal carcinogenesis and tumor progression. BMC Cancer; 2008;8:320
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypoxia-inducible factor 1 alpha expression increases during colorectal carcinogenesis and tumor progression.
  • However, its role in the development of colorectal cancer is unknown.
  • To investigate the significance of HIF-1alpha during colorectal carcinogenesis and progression we examined its expression in precursor lesions constituting the conventional and serrated pathways, as well as in non-metastatic and metastatic adenocarcinomas.
  • METHODS: Immunohistochemistry and Western blot is used to analyse HIF-1alpha expression in normal colonic mucosa, hyperplastic polyps (HPP), sessile serrated adenomas (SSA), low-grade (TA-LGD) and high-grade (TA-HGD) traditional adenomas as well as in non-metastatic and metastatic colorectal adenocarcinomas.
  • Eight colorectal carcinoma cell lines are tested for their HIF-1alpha inducibility after lipopolysaccharide (LPS) stimulation using western blot and immunocytochemistry.
  • In all investigated colorectal carcinomas a significant nuclear HIF-1alpha overexpression compared to the premalignant lesions was observed but a significant correlation with the metastatic status was not found.
  • In additional in vitro studies, treatment of diverse colorectal carcinoma cell lines with the potent pro-inflammatory factor lipopolysaccharide (LPS) led to HIF-1alpha expression and nuclear translocation.
  • CONCLUSION: We conclude that HIF-1alpha expression occurs in early stages of colorectal carcinogenesis and achieves a maximum in the invasive stage independent of the metastatic status.
  • [MeSH-major] Cell Transformation, Neoplastic / metabolism. Colorectal Neoplasms / metabolism. Colorectal Neoplasms / pathology. Hypoxia-Inducible Factor 1, alpha Subunit / biosynthesis. Precancerous Conditions / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Colorectal Cancer. 2006 Jan;5(5):350-3 [16512994.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):632-7 [16423989.001]
  • [Cites] Biochem J. 2006 Jun 15;396(3):517-27 [16533170.001]
  • [Cites] Histopathology. 2006 Aug;49(2):121-31 [16879389.001]
  • [Cites] Cancer Res. 1999 Nov 15;59(22):5830-5 [10582706.001]
  • [Cites] Genes Dev. 2000 Jan 1;14(1):34-44 [10640274.001]
  • [Cites] Am J Pathol. 2000 Aug;157(2):411-21 [10934146.001]
  • [Cites] Am J Surg. 2000 Jul;180(1):65-72 [11036145.001]
  • [Cites] J Natl Cancer Inst. 2001 Feb 21;93(4):309-14 [11181778.001]
  • [Cites] Lancet. 2001 Feb 17;357(9255):539-45 [11229684.001]
  • [Cites] J Natl Cancer Inst. 2001 Aug 1;93(15):1175-7 [11481392.001]
  • [Cites] Am J Pathol. 2001 Dec;159(6):2107-16 [11733361.001]
  • [Cites] Nat Rev Cancer. 2002 Jan;2(1):38-47 [11902584.001]
  • [Cites] Exp Mol Pathol. 2002 Aug;73(1):46-53 [12127053.001]
  • [Cites] J Mol Diagn. 2002 Nov;4(4):191-200 [12411586.001]
  • [Cites] J Biol Chem. 2002 Dec 20;277(51):50081-6 [12401798.001]
  • [Cites] World J Gastroenterol. 2006 Aug 7;12(29):4660-4 [16937436.001]
  • [Cites] Br J Cancer. 2007 Jan 15;96(1):95-103 [17179985.001]
  • [Cites] J Mol Med (Berl). 2007 Feb;85(2):139-48 [17180667.001]
  • [Cites] Pathol Oncol Res. 2007;13(1):15-20 [17387384.001]
  • [Cites] Cancer Res. 2007 Apr 1;67(7):3177-84 [17409425.001]
  • [Cites] Cell Oncol. 2007;29(3):219-27 [17452774.001]
  • [Cites] Int J Mol Med. 2007 Jul;20(1):21-9 [17549384.001]
  • [Cites] J Immunol. 2007 Jun 15;178(12):7516-9 [17548584.001]
  • [Cites] Int J Oncol. 2007 Aug;31(2):269-75 [17611682.001]
  • [Cites] World J Gastroenterol. 2007 Jul 28;13(28):3784-91 [17657831.001]
  • [Cites] Methods Enzymol. 2007;435:405-19 [17998066.001]
  • [Cites] Int J Oncol. 2008 Mar;32(3):585-92 [18292935.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):1138-43 [12615733.001]
  • [Cites] World J Gastroenterol. 2003 Mar;9(3):491-4 [12632503.001]
  • [Cites] Int J Cancer. 2003 Jun 10;105(2):176-81 [12673675.001]
  • [Cites] Mol Cell Biol. 2003 May;23(9):3265-73 [12697826.001]
  • [Cites] Am J Pathol. 2003 Jun;162(6):1789-806 [12759237.001]
  • [Cites] Nat Rev Cancer. 2003 Oct;3(10):721-32 [13130303.001]
  • [Cites] Blood. 2004 Feb 1;103(3):1124-30 [14525767.001]
  • [Cites] Cancer Detect Prev. 2004;28(2):88-93 [15068831.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):3082-90 [15131047.001]
  • [Cites] Shock. 2004 Sep;22(3):270-7 [15316398.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] Am J Surg Pathol. 1990 Jun;14(6):524-37 [2186644.001]
  • [Cites] Immunobiology. 1993 Apr;187(3-5):212-26 [7687233.001]
  • [Cites] Oncologist. 2004;9 Suppl 5:10-7 [15591418.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8554-60 [15623639.001]
  • [Cites] Am J Pathol. 2005 Apr;166(4):1069-75 [15793287.001]
  • [Cites] Cancer Res. 2005 Jun 1;65(11):4690-7 [15930287.001]
  • [Cites] Nat Clin Pract Oncol. 2005 Aug;2(8):398-405 [16130936.001]
  • [Cites] Cancer Lett. 2006 Jun 8;237(1):10-21 [16002209.001]
  • (PMID = 18983642.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Lipopolysaccharides
  • [Other-IDs] NLM/ PMC2584660
  •  go-up   go-down


33. Chen YJ, Shieh CJ, Tsai TH, Kuo CD, Ho LT, Liu TY, Liao HF: Inhibitory effect of norcantharidin, a derivative compound from blister beetles, on tumor invasion and metastasis in CT26 colorectal adenocarcinoma cells. Anticancer Drugs; 2005 Mar;16(3):293-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibitory effect of norcantharidin, a derivative compound from blister beetles, on tumor invasion and metastasis in CT26 colorectal adenocarcinoma cells.
  • A cytotoxicity assay of NCTD in CT26 colorectal adenocarcinoma cells showed a dose- and time-dependent decrease in cell viability.
  • [MeSH-major] Adenocarcinoma / enzymology. Bicyclo Compounds, Heterocyclic / pharmacology. Colorectal Neoplasms / enzymology. Lung Neoplasms / prevention & control. Matrix Metalloproteinase Inhibitors

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15711181.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bicyclo Compounds, Heterocyclic; 0 / Matrix Metalloproteinase Inhibitors; 5442-12-6 / norcantharidin; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


34. Barresi V, Vitarelli E, Tuccari G, Barresi G: Correlative study of microvessel density and 5-lipoxygenase expression in human sporadic colorectal cancer. Arch Pathol Lab Med; 2008 Nov;132(11):1807-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlative study of microvessel density and 5-lipoxygenase expression in human sporadic colorectal cancer.
  • CONTEXT: 5-Lipoxygenase (5-LO) is an arachidonic acid- metabolizing enzyme, which has been demonstrated to exert a role in colorectal cancer tumorigenesis.
  • Its activity in promoting neoangiogenesis in colorectal malignancies has been also recently theorized on the basis of in vitro studies.
  • OBJECTIVE: To investigate whether any correlation existed between 5-LO immunoexpression amount and the quantity of neoangiogenesis, as reflected by microvessel density (MVD) in human sporadic surgically resected colorectal adenocarcinomas.
  • DESIGN: A total of 45 formalin-fixed, paraffin-embedded colorectal adenocarcinomas were submitted to the immunohistochemical procedures for 5-LO and CD105, which represent specific markers for neoangiogenesis and which were used in the assessment of MVD.
  • CONCLUSIONS: Our study demonstrates the existence of a relationship between 5-LO expression and the neoangiogenesis process as reflected by intratumoral MVD in human sporadic colorectal adenocarcinomas, thus suggesting that 5-LO may modulate the formation of blood vessels in these neoplasias.
  • [MeSH-major] Adenocarcinoma / blood supply. Adenocarcinoma / enzymology. Arachidonate 5-Lipoxygenase / metabolism. Colorectal Neoplasms / blood supply. Colorectal Neoplasms / enzymology. Neovascularization, Pathologic / metabolism

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18976020.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / ENG protein, human; 0 / Receptors, Cell Surface; EC 1.13.11.34 / Arachidonate 5-Lipoxygenase
  •  go-up   go-down


35. Lualdi M, Colombo A, Leo E, Morelli D, Vannelli A, Battaglia L, Poiasina E, Marchesini R: Natural fluorescence spectroscopy of human blood plasma in the diagnosis of colorectal cancer: feasibility study and preliminary results. Tumori; 2007 Nov-Dec;93(6):567-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Natural fluorescence spectroscopy of human blood plasma in the diagnosis of colorectal cancer: feasibility study and preliminary results.
  • AIM AND BACKGROUND: Fluorescence spectroscopy of biomolecules is considered a promising method to discriminate in vivo normal tissue from malignant tissue at various sites including breast, cervix, lung, and colon.
  • In this study, the fluorescence characteristics of human blood plasma have been studied in the visible spectral range in an attempt to discriminate patients with colorectal cancer from subjects of a control population.
  • PATIENTS AND METHODS: The study involved 341 subjects, including 169 blood donors with no evidence of disease, 143 patients bearing colorectal adenocarcinomas (36 in the colon, 38 in the sigmoid colon and 69 in the rectum), 11 patients with local relapse, 10 patients with familial adenomatous polyposis and 8 with single adenomas.
  • RESULTS: The intensity of a fluorescence emission peak around 615-635 nm, which could reasonably be ascribed to endogenous porphyrins, was significantly different between patients bearing colorectal cancer and blood donors.
  • CONCLUSION: These results, although preliminary, suggest the potential of fluorescence measurements of blood plasma as an additional method for diagnostic application in colon cancer.
  • [MeSH-major] Biomarkers, Tumor / blood. Colorectal Neoplasms / diagnosis. Plasma. Porphyrins / blood. Spectrometry, Fluorescence
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenoma / diagnosis. Adenomatous Polyposis Coli / diagnosis. Adult. Aged. Area Under Curve. Blood Donors. Feasibility Studies. Female. Humans. Male. Middle Aged. ROC Curve

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18338491.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Porphyrins
  •  go-up   go-down


36. Donohoe CL, Pidgeon GP, Lysaght J, Reynolds JV: Obesity and gastrointestinal cancer. Br J Surg; 2010 May;97(5):628-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Numerous epidemiological studies consistently identified an increased risk of developing oesophageal adenocarcinoma and colorectal carcinoma in the obese.

  • Genetic Alliance. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Obesity.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 British Journal of Surgery Society Ltd.
  • (PMID = 20306531.001).
  • [ISSN] 1365-2168
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 156
  •  go-up   go-down


37. Guzinska-Ustymowicz K, Kemona A: Transforming growth factor beta can be a parameter of aggressiveness of pT1 colorectal cancer. World J Gastroenterol; 2005 Feb 28;11(8):1193-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transforming growth factor beta can be a parameter of aggressiveness of pT1 colorectal cancer.
  • AIM: To evaluate the significance of transforming growth factor beta (TGF beta) expression, in correlation with histopathological parameters, at the front of invasion in T1 colorectal cancer (CRC) and presence of metastases.
  • METHODS: TGF beta immunohistochemical expression was studied in 34 specimens of colorectal adenocarcinomas (pT1).
  • [MeSH-major] Colorectal Neoplasms / metabolism. Colorectal Neoplasms / pathology. Transforming Growth Factor beta / metabolism

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15754403.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Transforming Growth Factor beta
  • [Other-IDs] NLM/ PMC4250712
  •  go-up   go-down


38. Simsek BC, Pehlivan S, Karaoglu A: Human telomerase reverse transcriptase expression in colorectal tumors: correlations with immunohistochemical expression and clinicopathologic features. Ann Diagn Pathol; 2010 Dec;14(6):413-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human telomerase reverse transcriptase expression in colorectal tumors: correlations with immunohistochemical expression and clinicopathologic features.
  • Human telomerase reverse transcriptase (hTERT) proteins in colorectal cancer investigated in several studies, but to our knowledge, hTERT expression has not been evaluated in all of colorectal tumors, including hyperplastic polyps (HPs), adenomas, and carcinomas, on paraffin-embedded tissue sections.
  • The aim of the present study is to investigate immunohistochemical hTERT expression and its relationship with the clinicopathologic features in a spectrum of colorectal tumors.
  • In this study, hTERT expression was determined in HP (n = 20), adenomatous polyp (AP) (n = 20), colorectal adenocarcinomas (n = 20), and normal mucosa (n = 20) by immunohistochemical method.
  • Thereby, hTERT expression may use the aggressiveness of the colorectal tumors as a marker, but it is not related to clinicopathologic data.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Adenomatous Polyps / metabolism. Colorectal Neoplasms / metabolism. Telomerase / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 21074689.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


39. Falguières T, Maak M, von Weyhern C, Sarr M, Sastre X, Poupon MF, Robine S, Johannes L, Janssen KP: Human colorectal tumors and metastases express Gb3 and can be targeted by an intestinal pathogen-based delivery tool. Mol Cancer Ther; 2008 Aug;7(8):2498-508
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human colorectal tumors and metastases express Gb3 and can be targeted by an intestinal pathogen-based delivery tool.
  • The aim of this study was to expand these experiments to human colorectal cancer.
  • Tissue samples of normal colon, benign adenomas, colorectal carcinomas, and liver metastases from 111 patients were obtained for the quantification of the expression of the cellular STxB receptor, the glycosphingolipid globotriaosyl ceramide (Gb(3) or CD77).
  • We found that compared with normal tissue, the expression of Gb(3) was strongly increased in colorectal adenocarcinomas and their metastases, but not in benign adenomas.
  • In conclusion, the targeting properties of STxB could be diverted for the delivery of contrast agents to human colorectal tumors and their metastases, whose early detection and specific targeting remains one of the principal challenges in oncology.
  • [MeSH-major] Antigens, Tumor-Associated, Carbohydrate / biosynthesis. Colorectal Neoplasms / therapy. Intestines / microbiology. Shiga Toxins / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18687997.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Gb3 antigen; 0 / Shiga Toxins; 0 / Trihexosylceramides; 0 / stxB toxin; 71965-57-6 / globotriaosylceramide
  •  go-up   go-down


40. Cathomas R, Geldart TR, Iveson T, Singh N, Rowen D: An unusual differential diagnosis of penile warts: metastases from rectal carcinoma. Int J STD AIDS; 2006 Jul;17(7):491-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual differential diagnosis of penile warts: metastases from rectal carcinoma.
  • Their diagnosis is usually based on clinical observation and biopsy is not generally undertaken.
  • Penile metastases arise most frequently from genitourinary cancers (prostate, bladder and kidney), but may also arise from tumours of the large bowel; other primary sites are extremely uncommon.
  • [MeSH-major] Adenocarcinoma / secondary. Penile Neoplasms / secondary. Penis / pathology. Rectal Neoplasms / pathology. Warts / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans. Male. Middle Aged. Penile Diseases / diagnosis. Penile Diseases / pathology

  • MedlinePlus Health Information. consumer health - Warts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16820084.001).
  • [ISSN] 0956-4624
  • [Journal-full-title] International journal of STD & AIDS
  • [ISO-abbreviation] Int J STD AIDS
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


41. Zhou ZY, Han Y, Wang LP: [BRAF mutation in colorectal serrated lesions]. Zhonghua Yi Xue Za Zhi; 2008 Dec 30;88(48):3411-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [BRAF mutation in colorectal serrated lesions].
  • OBJECTIVE: To investigate the viral oncogene homolog B1 (BRAF) mutation frequency in serrated colorectal adenocarcinoma (Sca), and to verify the existence of a new serrated pathway indirectly.
  • METHODS: 75 paraffin-embedded tissue samples, including 15 cases of Sca, 20 cases of traditional serrated adenoma (TSA), 20 cases of non-serrated adenocarcinoma (NS-ca), and 20 cases of villous adenoma, were reviewed.
  • [MeSH-major] Adenocarcinoma / genetics. Adenoma / genetics. Colorectal Neoplasms / genetics. Proto-Oncogene Proteins B-raf / genetics


42. Cho YG, Choi BJ, Kim CJ, Song JW, Kim SY, Nam SW, Lee SH, Yoo NJ, Lee JY, Park WS: Genetic alterations of the KLF6 gene in colorectal cancers. APMIS; 2006 Jun;114(6):458-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic alterations of the KLF6 gene in colorectal cancers.
  • To investigate whether the KLF6 gene plays an important role in the development and/or progression of colorectal cancers, we searched for mutations and allelic loss of the KLF6 gene in 123 colorectal adenocarcinomas by performing PCR-SSCP sequencing.
  • These data further support that the KLF6 gene may be one of the candidate tumor suppressor genes in colorectal cancers and that genetic alteration of the KLF6 gene might play a role in the development of colorectal carcinomas.
  • [MeSH-major] Adenocarcinoma / genetics. Colorectal Neoplasms / genetics. Kruppel-Like Transcription Factors / genetics. Proto-Oncogene Proteins / genetics

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16856969.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / KLF6 protein, human; 0 / Kruppel-Like Transcription Factors; 0 / Proto-Oncogene Proteins
  •  go-up   go-down


43. Leslie A, Stewart A, Baty DU, Mechan D, McGreavey L, Smith G, Wolf CR, Sales M, Pratt NR, Steele RJ, Carey FA: Chromosomal changes in colorectal adenomas: relationship to gene mutations and potential for clinical utility. Genes Chromosomes Cancer; 2006 Feb;45(2):126-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosomal changes in colorectal adenomas: relationship to gene mutations and potential for clinical utility.
  • Although the occurrence of both chromosomal aberrations and specific gene mutations in colorectal tumorigenesis is firmly established, the relationship between these different forms of genetic abnormality remains poorly understood.
  • We have previously demonstrated, in colorectal adenocarcinomas, that mutations of APC, KRAS, and TP53 are each specifically associated with certain chromosomal aberrations.
  • Using comparative genomic hybridization and mutational analysis of APC, KRAS, and TP53 to evaluate 78 colorectal adenomas, we have shown that several of the significant relationships between gene mutations and chromosomal abnormalities reported in colorectal adenocarcinomas also exist at the adenomatous stage.
  • [MeSH-major] Adenoma / genetics. Chromosome Aberrations. Colorectal Neoplasms / genetics. Mutation

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16235243.001).
  • [ISSN] 1045-2257
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


44. Taweevisit M: The association of stromal mast cell response and tumor cell differentiation in colorectal cancer. J Med Assoc Thai; 2006 Sep;89 Suppl 3:S69-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The association of stromal mast cell response and tumor cell differentiation in colorectal cancer.
  • BACKGROUND: Resembling other neoplasms, the colorectal carcinogenesis is still a riddle in various aspects.
  • OBJECTIVE: To evaluate the relation between mast cell number and biology of colorectal adenocarcinoma.
  • MATERIAL AND METHOD: The author collected 162 cases, diagnosed as primary adenocarcinoma of the colon at the King Chulalongkorn Memorial Hospital, between 2002 and 2003, for evaluating the role of mast cells in colorectal cancers.
  • CONCLUSION: This observation might indicate that mast cell function has a role in colorectal pathogenesis.
  • [MeSH-major] Adenocarcinoma / pathology. Colorectal Neoplasms / pathology. Mast Cells / pathology. Stromal Cells / pathology

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17718271.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


45. Elias D, Glehen O, Pocard M, Quenet F, Goéré D, Arvieux C, Rat P, Gilly F, Association Française de Chirurgie: A comparative study of complete cytoreductive surgery plus intraperitoneal chemotherapy to treat peritoneal dissemination from colon, rectum, small bowel, and nonpseudomyxoma appendix. Ann Surg; 2010 May;251(5):896-901
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comparative study of complete cytoreductive surgery plus intraperitoneal chemotherapy to treat peritoneal dissemination from colon, rectum, small bowel, and nonpseudomyxoma appendix.
  • OBJECTIVE: To report a large number of patients with peritoneal carcinomatosis (PC) treated with complete cytoreductive (CCR-0) plus intraperitoneal chemotherapy, and to compare the results according to the origin of the primary: colon, rectum, small bowel, and appendix (excluding peritoneal pseudomyxoma).
  • Primary sites were: colon (n=341), rectum (n=27), appendix (n=41), and small bowel (n=31).
  • The 5-year overall survival rates were not statistically different for the colon (29.7%), rectum (37.9%), nor the small bowel (33.8%), but was higher (P=0.01) for appendix adenocarcinoma (63.2%).
  • CONCLUSION: Cytoreductive surgery plus intraperitoneal chemotherapy yields satisfying and similar survival results in the treatment of PC from colon, rectum, and small bowel adenocarcinomas.
  • Results were better for appendix adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Appendiceal Neoplasms / pathology. Colonic Neoplasms / pathology. Intestinal Neoplasms / pathology. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / surgery. Rectal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20395843.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Wong MT, Eu KW: Rise of colorectal cancer in Singapore: an epidemiological review. ANZ J Surg; 2007 Jun;77(6):446-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rise of colorectal cancer in Singapore: an epidemiological review.
  • BACKGROUND: Over the past three decades, Singapore has seen a dramatic increase in the incidence of colorectal cancer and this is now the most frequent cancer when both genders are combined.
  • METHODS: In light of this alarming trend, a review of colorectal cancer in Singapore was conducted, using data from the Singapore Cancer Registry from 1968 to 2002.
  • RESULTS: Between 1998 and 2002, deaths from colorectal cancer constituted 19% of all cancer mortalities in men and 14% in women, accounting for the second highest cause of cancer mortality in both genders.
  • In the same period, more than three quarters (75.6%) of colorectal cancers occurred in the distal colon (including splenic flexure, descending, sigmoid colon and rectum), with the predominant histological subtype being adenocarcinoma (approximately 90%).
  • The age-specific rates for colorectal cancer begin to increase sharply in the 40- to 45-year age group.
  • In individuals aged 65 years and above, colorectal cancer remains prominent in both genders.
  • CONCLUSION: Despite the dramatic increase in incidence of colorectal cancer in Singapore, there has also been significant progress in survival of colorectal cancer patients with localized disease (limited to large bowel), with 5-year, age-standardized relative survival improving from 36 to 66% in men and 32 to 71% in women; in rectal cancer, improvements from 25 to 66% in men and 23 to 66% in women were also observed.
  • [MeSH-major] Colorectal Neoplasms / epidemiology
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adolescent. Adult. Aged. Aged, 80 and over. Asia, Southeastern / epidemiology. Child. Child, Preschool. Colonic Neoplasms / epidemiology. Female. Humans. Infant. Male. Middle Aged. Registries. Singapore / epidemiology

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17501884.001).
  • [ISSN] 1445-1433
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


47. Gómez Del Pulgar T, Valdés-Mora F, Bandrés E, Pérez-Palacios R, Espina C, Cejas P, García-Cabezas MA, Nistal M, Casado E, González-Barón M, García-Foncillas J, Lacal JC: Cdc42 is highly expressed in colorectal adenocarcinoma and downregulates ID4 through an epigenetic mechanism. Int J Oncol; 2008 Jul;33(1):185-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cdc42 is highly expressed in colorectal adenocarcinoma and downregulates ID4 through an epigenetic mechanism.
  • Here, the specific role of Cdc42 in development and progression of colorectal cancer was analyzed through microarrays technology.
  • Colorectal adenocarcinoma samples were compared with the corresponding adjacent normal tissue of the same patient in order to determine specific gene expression levels.
  • The downregulation of ID4 by Cdc42 was also found of relevance in colorectal adenocarcinoma biopsies.
  • Cdc42 was found to be overexpressed with high incidence (60%) in colorectal cancer samples, and this expression was associated with silencing of ID4 with statistical significance (p<0.05).
  • Cdc42 may have a role in the development of colon cancer.
  • Furthermore, inhibition of Cdc42 activity may have a direct impact in the management of colorectal cancer.
  • [MeSH-major] Adenocarcinoma / chemistry. Colorectal Neoplasms / chemistry. Inhibitor of Differentiation Proteins / genetics. cdc42 GTP-Binding Protein / physiology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18575765.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / ID4 protein, human; 0 / Inhibitor of Differentiation Proteins; EC 3.6.5.2 / cdc42 GTP-Binding Protein
  •  go-up   go-down


48. Tan LT, Zahra M: Long-term survival and late toxicity after chemoradiotherapy for cervical cancer--the Addenbrooke's experience. Clin Oncol (R Coll Radiol); 2008 Jun;20(5):358-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Forty-seven (66.2%) patients had squamous cell carcinomas, whereas 24 (33.8%) patients had adenocarcinomas.
  • Eight of 23 patients (34.8%) with adenocarcinomas developed metastatic disease compared with only six of 43 patients (14.0%) with squamous cell tumours.
  • Six patients (8.5%) had grade 3 or 4 urinary complications, five (7.0%) had grade 3 or 4 bowel complications and six (8.5%) had grade 3 or 4 complications affecting other organs.
  • The actuarial rate for grade 3 or 4 urinary complications was 14.5%, 9.4% for grade 3 or 4 bowel complications and 11.4% for grade 3 or 4 complications affecting other organs.
  • CONCLUSIONS: Our study has shown that the addition of chemotherapy to radiotherapy for cervical cancer probably improves the survival of patients treated outside research settings, but the benefit may not be as large as that obtained in clinical trials and the risk of serious late toxicity is increased.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Antineoplastic Agents / adverse effects. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Radiotherapy / adverse effects. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • Hazardous Substances Data Bank. PLATINUM COMPOUNDS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18395427.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Platinum Compounds
  •  go-up   go-down


49. Wittig A, Malago M, Collette L, Huiskamp R, Bührmann S, Nievaart V, Kaiser GM, Jöckel KH, Schmid KW, Ortmann U, Sauerwein WA: Uptake of two 10B-compounds in liver metastases of colorectal adenocarcinoma for extracorporeal irradiation with boron neutron capture therapy (EORTC Trial 11001). Int J Cancer; 2008 Mar 1;122(5):1164-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uptake of two 10B-compounds in liver metastases of colorectal adenocarcinoma for extracorporeal irradiation with boron neutron capture therapy (EORTC Trial 11001).
  • Disseminated metastases of colorectal cancer in liver are incurable.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Boron Compounds / pharmacokinetics. Boron Neutron Capture Therapy / methods. Colorectal Neoplasms / pathology. Liver Neoplasms / radiotherapy. Phenylalanine / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. BORON COMPOUNDS .
  • Hazardous Substances Data Bank. (L)-Phenylalanine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17985341.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Boron Compounds; 12008-78-5 / dodecaborate; 47E5O17Y3R / Phenylalanine; UID84303EL / 4-boronophenylalanine
  •  go-up   go-down


50. Mäkelä JT, Kiviniemi H: Clinicopathological features of colorectal cancer in patients under 40 years of age. Int J Colorectal Dis; 2010 Jul;25(7):823-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological features of colorectal cancer in patients under 40 years of age.
  • OBJECTIVE: The aim was to identify the clinical factors and tumour characteristics that predict survival in patients younger than 40 years with colorectal adenocarcinoma.
  • MATERIAL AND METHODS: Fifty-nine patients with colorectal cancer aged under 40 years were identified from a computer database, and their clinical variables were analysed.
  • CONCLUSIONS: Young men with colorectal cancer in Northern Finland have poorer prognosis than women.
  • [MeSH-major] Colorectal Neoplasms / pathology

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2009 Mar 24;100(6):881-7 [19259089.001]
  • [Cites] Int J Colorectal Dis. 2006 Sep;21(6):596-601 [16284773.001]
  • [Cites] Arch Surg. 1995 Oct;130(10):1062-7 [7575117.001]
  • [Cites] Br J Surg. 2003 Feb;90(2):205-14 [12555297.001]
  • [Cites] J Am Coll Surg. 1996 Aug;183(2):105-12 [8696540.001]
  • [Cites] Br J Surg. 1998 Sep;85(9):1255-9 [9752871.001]
  • [Cites] Gastroenterology. 1988 Feb;94(2):395-400 [3335314.001]
  • [Cites] N Engl J Med. 1994 Dec 22;331(25):1669-74 [7969357.001]
  • [Cites] N Engl J Med. 2009 Feb 5;360(6):563-72 [19196673.001]
  • [Cites] Dis Colon Rectum. 1986 May;29(5):322-5 [3009108.001]
  • [Cites] Dis Colon Rectum. 1997 Jan;40(1):3-10 [9102257.001]
  • [Cites] Dis Colon Rectum. 1991 Apr;34(4):343-6 [1706654.001]
  • [Cites] Am J Surg. 2004 Mar;187(3):343-8 [15006562.001]
  • [Cites] Dis Colon Rectum. 2006 Sep;49(9):1275-83 [16912910.001]
  • [Cites] Dis Colon Rectum. 2000 Sep;43(9):1222-6 [11005487.001]
  • [Cites] Am J Gastroenterol. 1997 Sep;92(9):1505-9 [9317073.001]
  • [Cites] Dis Colon Rectum. 1996 Sep;39(9):1004-7 [8797650.001]
  • [Cites] Dis Colon Rectum. 1980 Jul-Aug;23(5):327-36 [7398507.001]
  • [Cites] Dis Colon Rectum. 1989 Oct;32(10):843-6 [2791769.001]
  • [Cites] Dis Colon Rectum. 1990 May;33(5):363-6 [2328623.001]
  • [Cites] Scand J Gastroenterol. 1984 Jul;19(5):634-8 [6474085.001]
  • [Cites] Ann Surg. 1967 Sep;166(3):420-7 [6039601.001]
  • [Cites] Ann Oncol. 2005 Aug;16(8):1305-10 [15857840.001]
  • [Cites] Cancer. 1988 Feb 15;61(4):835-40 [3338041.001]
  • [Cites] Dis Colon Rectum. 2001 Mar;44(3):380-7 [11289284.001]
  • (PMID = 20217423.001).
  • [ISSN] 1432-1262
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


51. Wei YC, Zhou FL, He DL, Bai JR, Hui LY, Wang XY, Nan KJ: The level of oxidative stress and the expression of genes involved in DNA-damage signaling pathways in depressive patients with colorectal carcinoma. J Psychosom Res; 2009 Mar;66(3):259-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The level of oxidative stress and the expression of genes involved in DNA-damage signaling pathways in depressive patients with colorectal carcinoma.
  • OBJECTIVES: This study investigated the connection among the oxidative stress, depression and expression of specific genes involved in DNA-damage signaling pathways in patients with colorectal carcinoma (CRC).
  • METHODS: A unique Dukes'C subset of patients with newly diagnosed colorectal adenocarcinoma were assessed using the Hamilton Depression Rating Scale (HAMD), Zung Self-rating Depression Scale (SDS), Zung Self-rating Anxiety Scale (SAS), Symptom Checklist 90 (SCL-90) and other multiple-item questionnaires.
  • [MeSH-major] Adenocarcinoma / genetics. Colorectal Neoplasms / genetics. DNA Damage / genetics. Depressive Disorder / genetics. Gene Expression Regulation, Neoplastic / genetics. Oxidative Stress / genetics. Signal Transduction / genetics

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. GUANINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19232240.001).
  • [ISSN] 0022-3999
  • [Journal-full-title] Journal of psychosomatic research
  • [ISO-abbreviation] J Psychosom Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 5Z93L87A1R / Guanine; 6957-76-2 / 8-oxo-7,8-dihydrodeoxyguanine
  •  go-up   go-down


52. Nakagawa Y, Iinuma M, Naoe T, Nozawa Y, Akao Y: Characterized mechanism of alpha-mangostin-induced cell death: caspase-independent apoptosis with release of endonuclease-G from mitochondria and increased miR-143 expression in human colorectal cancer DLD-1 cells. Bioorg Med Chem; 2007 Aug 15;15(16):5620-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterized mechanism of alpha-mangostin-induced cell death: caspase-independent apoptosis with release of endonuclease-G from mitochondria and increased miR-143 expression in human colorectal cancer DLD-1 cells.
  • ), was evaluated for in vitro cytotoxicity against human colon cancer DLD-1 cells.
  • We also examined the synergistic growth suppression in DLD-1 cells by the combined treatment of the cells with alpha-mangostin and 5-FU which is one of the most effective chemotherapeutic agents for colorectal adenocarcinoma.
  • [MeSH-major] Apoptosis / drug effects. Colorectal Neoplasms / metabolism. Colorectal Neoplasms / pathology. Endodeoxyribonucleases / secretion. MicroRNAs / genetics. Mitochondria / drug effects. Xanthones / pharmacology


53. Krakowczyk L, Blamek S, Strzelczyk JK, Plachetka A, Maciejewski A, Połtorak S, Wiczkowski A: Effects of X-ray irradiation on methylation levels of p16, MGMT and APC genes in sporadic colorectal carcinoma and corresponding normal colonic mucosa. Med Sci Monit; 2010 Oct;16(10):CR469-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of X-ray irradiation on methylation levels of p16, MGMT and APC genes in sporadic colorectal carcinoma and corresponding normal colonic mucosa.
  • BACKGROUND: Colorectal cancer, one of the most aggressive cancers, occurs with a high incidence world-wide.
  • In the current study we evaluated the effect of X-ray irradiation on methylation levels of p16, MGMT and APC genes in colorectal cancers and normal colonic mucosa.
  • MATERIAL/METHODS: Fresh tissue samples were obtained from 28 patients (ages 26 to 81 years) with primary colorectal adenocarcinoma and corresponding normal tissues.
  • [MeSH-major] Colorectal Neoplasms / genetics. DNA Methylation / radiation effects. Genes, APC. Genes, p16. O(6)-Methylguanine-DNA Methyltransferase / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Colon / metabolism. Colon / pathology. Humans. Intestinal Mucosa / metabolism. Intestinal Mucosa / pathology. Middle Aged. X-Rays

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20885350.001).
  • [ISSN] 1643-3750
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  •  go-up   go-down


54. Porjazova E, Zaprjanov Z, Batashki I, Markova D, Milchev N: [Immunohistochemical profile of colorectal and ovarian carcinomas--examination with cytokeratin 7, cytokeratin 20, beta catenin and cDX 2]. Akush Ginekol (Sofiia); 2009;48(2):7-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Immunohistochemical profile of colorectal and ovarian carcinomas--examination with cytokeratin 7, cytokeratin 20, beta catenin and cDX 2].
  • INTRODUCTION: Metastases from colorectal adenocarcinomas can be histologically similar to serous, mucinous and endometrioid ovarian adenocarcinomas.
  • MATERIALS AND METHODS: The immunohistochemical expression of the listed above antibodies was examined retrospectively and prospectively in 38 colorectal adenocarcinomas (primary and metastatic) and 32 ovarian adenocarcinomas (primary and metastatic).
  • The metastases in both types of adenocarcinomas are located in the peritoneum.
  • The ovarian adenocarcinomas are mostly positive for Cytokeratin 7 (in 63%), while colorectal carcinomas are mostly positive for Cytokeratin 20 (in 73%).
  • Regarding Beta catenin, in colorectal carcinomas the expression is mostly nuclear (in 65%) and in ovarian carcinomas mostly membrane (in 68%).
  • CONCLUSION: For differential diagnosis between ovarian and colorectal adenocarcinomas, the use of antibodies, determining the intestinal differentiation of the tumours like Cytokeratin 20, Beta catenin and CDX2 is recommended.
  • [MeSH-major] Adenocarcinoma / diagnosis. Colorectal Neoplasms / diagnosis. Homeodomain Proteins / analysis. Keratin-20 / analysis. Keratin-7 / analysis. Ovarian Neoplasms / diagnosis. Trans-Activators / analysis. beta Catenin / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies / analysis. Antibodies / immunology. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Middle Aged. Prospective Studies. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20198769.001).
  • [ISSN] 0324-0959
  • [Journal-full-title] Akusherstvo i ginekologii︠a︡
  • [ISO-abbreviation] Akush Ginekol (Sofiia)
  • [Language] bul
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Bulgaria
  • [Chemical-registry-number] 0 / Antibodies; 0 / Homeodomain Proteins; 0 / Keratin-20; 0 / Keratin-7; 0 / Trans-Activators; 0 / beta Catenin; 156560-97-3 / Cdx-2-3 protein
  •  go-up   go-down


55. Lewis MR, Euscher ED, Deavers MT, Silva EG, Malpica A: Metastatic colorectal adenocarcinoma involving the ovary with elevated serum CA125: a potential diagnostic pitfall. Gynecol Oncol; 2007 May;105(2):395-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic colorectal adenocarcinoma involving the ovary with elevated serum CA125: a potential diagnostic pitfall.
  • There is considerable overlap in gross and histologic features between primary ovarian tumors and metastatic colorectal adenocarcinoma, which can make diagnosis particularly challenging in the setting of an increased CA125 level.
  • The aims of this study were to determine how frequently serum CA125 is elevated in women with ovarian involvement by metastatic colorectal adenocarcinoma and to compare the features of cases with and without associated elevations of serum CA125.
  • METHODS: Eighty-nine cases of histologically confirmed ovarian involvement by metastatic colorectal adenocarcinoma were identified by retrospective review.
  • CONCLUSIONS: At least 32.6% of women with ovarian involvement by metastatic colorectal adenocarcinoma have an elevated serum CA125 level prior to oophorectomy.
  • The possibility of metastasis from a colorectal carcinoma merits consideration in the formation of the differential diagnosis for a woman with an adnexal mass and elevated serum CA125, even in the absence of an established history of gastrointestinal malignancy.
  • [MeSH-major] Adenocarcinoma / blood. Adenocarcinoma / secondary. CA-125 Antigen / blood. Colorectal Neoplasms / blood. Colorectal Neoplasms / pathology. Ovarian Neoplasms / blood. Ovarian Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17335881.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


56. Hashimoto Y, Skacel M, Adams JC: Association of loss of epithelial syndecan-1 with stage and local metastasis of colorectal adenocarcinomas: an immunohistochemical study of clinically annotated tumors. BMC Cancer; 2008;8:185
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of loss of epithelial syndecan-1 with stage and local metastasis of colorectal adenocarcinomas: an immunohistochemical study of clinically annotated tumors.
  • Loss of epithelial syndecan-1 has been reported in human colorectal adenocarcinomas, but whether this has prognostic significance remains undecided.
  • Here we have examined syndecan-1 expression and its potential prognostic value with reference to a clinically annotated tissue microarray for human colon adenocarcinomas.
  • METHODS: Syndecan-1 expression was examined by immunohistochemistry of a tissue microarray containing cores from 158 colorectal adenocarcinomas and 15 adenomas linked to a Cleveland Clinic, IRB-approved database with a mean clinical follow-up of 38 months.
  • On adenocarcinoma cells, syndecan-1 was present around cell membranes and in cytoplasm.
  • In 87% of adenocarcinomas, syndecan-1 was decreased or absent; only 13% of patients had stained for syndecan-1 on more than 75% of tumor cells.
  • CONCLUSION: Syndecan-1 immunoreactivity was decreased in the majority of human colon adenocarcinomas in correlation with TNM stage and metastasis to local lymph nodes.
  • In a small fraction of adenocarcinomas, syndecan-1 was upregulated in the local stroma.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Colorectal Neoplasms / metabolism. Colorectal Neoplasms / pathology. Syndecan-1 / biosynthesis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BMC Genomics. 2006;7:83 [16620374.001]
  • [Cites] Oral Oncol. 2006 May;42(5):493-500 [16364677.001]
  • [Cites] Respir Res. 2006;7:95 [16813649.001]
  • [Cites] BMC Cancer. 2006;6:241 [17029629.001]
  • [Cites] Int J Biochem Cell Biol. 2007;39(3):505-28 [17097330.001]
  • [Cites] Oncogene. 2007 Mar 1;26(10):1407-16 [16953225.001]
  • [Cites] Br J Cancer. 2007 Apr 10;96(7):1118-26 [17375048.001]
  • [Cites] Cancer Res. 2007 Jul 15;67(14):6844-53 [17638895.001]
  • [Cites] J Cell Sci. 2007 Aug 15;120(Pt 16):2851-63 [17666434.001]
  • [Cites] Annu Rev Pathol. 2006;1:119-50 [18039110.001]
  • [Cites] Clin Exp Metastasis. 2008;25(2):149-59 [18027090.001]
  • [Cites] Int J Cancer. 2000 Oct 1;88(1):12-20 [10962434.001]
  • [Cites] Curr Opin Oncol. 2001 Jan;13(1):63-9 [11148689.001]
  • [Cites] Int J Cancer. 2001 Jan 20;95(1):1-6 [11241302.001]
  • [Cites] J Cell Biol. 2001 Mar 19;152(6):1169-82 [11257118.001]
  • [Cites] Anticancer Res. 2000 Nov-Dec;20(6D):4905-7 [11326638.001]
  • [Cites] Jpn J Cancer Res. 2001 Oct;92(10):1074-81 [11676858.001]
  • [Cites] J Cell Sci. 2002 Dec 1;115(Pt 23):4517-31 [12414997.001]
  • [Cites] Oncogene. 2003 Dec 18;22(58):9243-53 [14681683.001]
  • [Cites] Eur J Cancer. 2004 Jun;40(9):1373-82 [15177497.001]
  • [Cites] Oncology. 2004;67(1):11-8 [15459490.001]
  • [Cites] Cell Regul. 1991 Jan;2(1):1-11 [2007184.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Feb 1;89(3):932-6 [1736308.001]
  • [Cites] Annu Rev Cell Biol. 1992;8:365-93 [1335744.001]
  • [Cites] J Biol Chem. 1994 Aug 5;269(31):20013-9 [8051085.001]
  • [Cites] Br J Cancer. 1994 Aug;70(2):319-23 [8054282.001]
  • [Cites] Br J Cancer. 1996 Aug;74(3):423-31 [8695359.001]
  • [Cites] J Cell Sci. 1996 Jun;109 ( Pt 6):1393-403 [8799827.001]
  • [Cites] Virchows Arch. 1999 Feb;434(2):121-5 [10071246.001]
  • [Cites] J Exp Clin Cancer Res. 2004 Dec;23(4):641-50 [15743035.001]
  • [Cites] Gynecol Oncol. 2005 Mar;96(3):776-83 [15810155.001]
  • [Cites] J Immunol. 2005 May 1;174(9):5758-65 [15843578.001]
  • [Cites] Ann Oncol. 2005 Jul;16(7):1109-15 [15851381.001]
  • [Cites] Mol Biol Cell. 2005 Aug;16(8):3678-91 [15930135.001]
  • [Cites] Oncology. 2005;68(4-6):306-13 [16020957.001]
  • [Cites] Anticancer Res. 2006 Jan-Feb;26(1B):621-7 [16739330.001]
  • (PMID = 18590537.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Microfilament Proteins; 0 / SDC1 protein, human; 0 / Syndecan-1; 146808-54-0 / fascin
  • [Other-IDs] NLM/ PMC2459187
  •  go-up   go-down


57. Suggitt M, Cooper PA, Shnyder SD, Bibby MC: The hollow fibre model--facilitating anti-cancer pre-clinical pharmacodynamics and improving animal welfare. Int J Oncol; 2006 Dec;29(6):1493-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Microscopy results revealed nuclear uptake and localisation within cytoplasmic organelles of HT29 colorectal adenocarcinoma cells following treatment with C1311 (150 mg/kg).

  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17088988.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / 1,1'-((propane-1,3-diyl)dioxy)bis(7-methoxy-2-methylidene-1,2,3,10,11,11a-hexahydro-5H-pyrrolo(2,1-c)(1,4)benzodiazepin-5,11-dione); 0 / Aminoacridines; 0 / Benzodiazepinones; 0 / Pyrroles; 138154-39-9 / C 1311; 50SG953SK6 / Mitomycin
  •  go-up   go-down


58. Huh JW, Park YA, Lee KY, Sohn SK: Heterogeneity of adenosine triphosphate-based chemotherapy response assay in colorectal cancer--secondary publication. Yonsei Med J; 2009 Oct 31;50(5):697-703
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heterogeneity of adenosine triphosphate-based chemotherapy response assay in colorectal cancer--secondary publication.
  • This study explored the feasibility of ATP-CRA as a chemosensitivity test in patients with colorectal cancer.
  • MATERIALS AND METHODS: A total of 118 patients who underwent surgical resection for colorectal adenocarcinoma were analyzed for chemosensitivity to 6 anticancer drugs using ATP-CRA.
  • CONCLUSION: Our study suggests that ATP-CRA could be used to identify patients with colorectal cancer who might benefit from treatment with a specific chemotherapeutic agent.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenosine Triphosphate / metabolism. Antineoplastic Agents / pharmacology. Colorectal Neoplasms / drug therapy. Drug Screening Assays, Antitumor / methods

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2000 Mar;76(3):405-8 [10684718.001]
  • [Cites] J Korean Med Sci. 2008 Oct;23(5):916-9 [18955806.001]
  • [Cites] Eur J Cancer. 2002 May;38(7):872-9 [11978511.001]
  • [Cites] Anticancer Drugs. 2003 Jun;14(5):369-75 [12782944.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):23-30 [14665611.001]
  • [Cites] J Clin Oncol. 2004 Jan 15;22(2):229-37 [14657227.001]
  • [Cites] Pharm Res. 2004 Mar;21(3):406-12 [15070089.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3618-30 [15289487.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3631-8 [15289488.001]
  • [Cites] Cancer Res. 1982 Jun;42(6):2159-64 [7074595.001]
  • [Cites] Cancer Treat Rev. 1984 Mar;11 Suppl A:113-24 [6428738.001]
  • [Cites] Recent Results Cancer Res. 1984;94:1-7 [6494573.001]
  • [Cites] Hematol Oncol. 1985 Jan-Mar;3(1):1-10 [2580768.001]
  • [Cites] Cancer Treat Rep. 1986 Nov;70(11):1283-95 [2429763.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Jul;84(14):5029-33 [3474637.001]
  • [Cites] Gynecol Oncol. 1988 Sep;31(1):191-204 [3410347.001]
  • [Cites] J Surg Oncol. 1989 Jan;40(1):4-7 [2909804.001]
  • [Cites] Eur J Cancer. 1991;27(10):1258-63 [1835595.001]
  • [Cites] J Biolumin Chemilumin. 1995 Jan-Feb;10(1):29-34 [7762413.001]
  • [Cites] Anticancer Drugs. 1996 Aug;7(6):630-5 [8913430.001]
  • [Cites] Eur J Cancer. 1997 May;33(6):960-6 [9291821.001]
  • [Cites] Ann Intern Med. 1998 Jul 1;129(1):27-35 [9652996.001]
  • [Cites] Clin Cancer Res. 1995 Mar;1(3):305-11 [9815986.001]
  • [Cites] Br J Cancer. 1999 Mar;79(9-10):1487-93 [10188895.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1625-31 [10334552.001]
  • [Cites] Anticancer Drugs. 1999 Jun;10(5):437-44 [10477162.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Anticancer Res. 2005 Sep-Oct;25(5):3453-9 [16101163.001]
  • [Cites] Cell Cycle. 2006 Apr;5(8):818-23 [16628000.001]
  • [Cites] Int J Clin Oncol. 2006 Dec;11(6):449-53 [17180513.001]
  • [Cites] Cancer. 2007 May 1;109(9):1829-35 [17366594.001]
  • [Cites] Gynecol Oncol. 2000 May;77(2):258-63 [10785475.001]
  • (PMID = 19881975.001).
  • [ISSN] 1976-2437
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 8L70Q75FXE / Adenosine Triphosphate
  • [Other-IDs] NLM/ PMC2768246
  • [Keywords] NOTNLM ; Adenosine triphosphate / chemotherapy response assay / colorectal cancer
  •  go-up   go-down


59. Efstathios P, Athanasios P, Papaconstantinou I, Alexandros P, Frangisca S, Sotirios G, Evangelos F, Athanasios G: Coexistence of gastrointestinal stromal tumor (GIST) and colorectal adenocarcinoma: A case report. World J Surg Oncol; 2007;5:96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coexistence of gastrointestinal stromal tumor (GIST) and colorectal adenocarcinoma: A case report.
  • CASE PRESENTATION: We present here, a case of a 66-year-old patient with intestinal GIST and a synchronous colorectal adenocarcinoma discovered incidentally during surgical treatment of the recurrent GIST.
  • Immunohistochemical examination revealed the concurrence of histologically proved GIST (strongly positive staining for c-kit, vimentin, SMA, and focal positive in S-100, while CD-34 was negative) and Dukes Stage C, (T3, N3, M0 according the TNM staging classification of colorectal cancer).
  • CONCLUSION: The coexistence of GIST with either synchronous or metachronous colorectal cancer represents a phenomenon with increasing number of relative reports in the literature the last 5 years.
  • The correct diagnosis before and at the time of the surgical procedure is the cornerstone that secures the patients' best prognosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch. 2001 Jan;438(1):1-12 [11213830.001]
  • [Cites] Ann Surg Oncol. 2000 Oct;7(9):705-12 [11034250.001]
  • [Cites] Hum Pathol. 2002 May;33(5):478-83 [12094372.001]
  • [Cites] Cancer Res. 2002 Sep 1;62(17):4879-83 [12208734.001]
  • [Cites] J Gastroenterol. 2002;37(11):947-53 [12483251.001]
  • [Cites] Int J Cancer. 2003 Nov 1;107(2):171-6 [12949790.001]
  • [Cites] Ann Oncol. 2004 May;15(5):843-4 [15111359.001]
  • [Cites] Med Sci Monit. 2004 Aug;10(8):LE13-4 [15278004.001]
  • [Cites] Cancer. 2004 Dec 1;101(11):2633-5 [15494976.001]
  • [Cites] Am J Gastroenterol. 2005 Jan;100(1):162-8 [15654796.001]
  • [Cites] Magy Onkol. 2004;48(4):315-21 [15655577.001]
  • [Cites] Ann Oncol. 2005 Apr;16(4):566-78 [15781488.001]
  • [Cites] J Clin Oncol. 2005 Aug 10;23(23):5357-64 [15928335.001]
  • [Cites] Z Gastroenterol. 2005 Sep;43(9):1025-30 [16142610.001]
  • [Cites] Eur J Cancer. 2005 Dec;41(18):2868-72 [16293410.001]
  • [Cites] World J Gastroenterol. 2006 Jan 28;12(4):665-7 [16489690.001]
  • [Cites] Int J Colorectal Dis. 2007 Feb;22(2):109-14 [16639561.001]
  • [Cites] World J Surg. 2006 Dec;30(12):2210-6 [17086376.001]
  • [Cites] Semin Diagn Pathol. 2006 May;23(2):120-9 [17193825.001]
  • [Cites] Cancer Res. 1970 Feb;30(2):455-65 [5458974.001]
  • [Cites] Cancer. 1982 Jan 1;49(1):177-87 [7053814.001]
  • [Cites] Virchows Arch. 1994;424(1):19-24 [7981899.001]
  • [Cites] Am J Clin Pathol. 1993 Oct;100(4):428-32 [8105676.001]
  • [Cites] Surgery. 1996 Feb;119(2):171-7 [8571202.001]
  • [Cites] Curr Probl Surg. 1996 Oct;33(10):817-72 [8885853.001]
  • [Cites] Ann Surg. 2000 Jan;231(1):51-8 [10636102.001]
  • [Cites] Arch Pathol Lab Med. 2000 May;124(5):682-6 [10782147.001]
  • [Cites] Am J Surg Pathol. 2000 Oct;24(10):1339-52 [11023095.001]
  • [Cites] Int J Surg Pathol. 2002 Apr;10(2):81-9 [12075401.001]
  • (PMID = 17708776.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2034569
  •  go-up   go-down


60. Nakas A, Klimatsidas MN, Entwisle J, Martin-Ucar AE, Waller DA: Video-assisted versus open pulmonary metastasectomy: the surgeon's finger or the radiologist's eye? Eur J Cardiothorac Surg; 2009 Sep;36(3):469-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Pulmonary metastasectomy was performed for metastatic colorectal adenocarcinoma in 52 patients: 27 open and 25 VATS over 8 years.
  • CONCLUSIONS: The selective use of VATS therapeutic metastasectomy in conjunction with multi-detector CT is justified in metastatic colorectal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Thoracic Surgery, Video-Assisted / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Colorectal Neoplasms / pathology. Disease Progression. Female. Humans. Liver Neoplasms / secondary. Male. Middle Aged. Neoplasm Recurrence, Local. Pneumonectomy / methods. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19464921.001).
  • [ISSN] 1873-734X
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


61. Goethals L, Debucquoy A, Perneel C, Geboes K, Ectors N, De Schutter H, Penninckx F, McBride WH, Begg AC, Haustermans KM: Hypoxia in human colorectal adenocarcinoma: comparison between extrinsic and potential intrinsic hypoxia markers. Int J Radiat Oncol Biol Phys; 2006 May 1;65(1):246-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypoxia in human colorectal adenocarcinoma: comparison between extrinsic and potential intrinsic hypoxia markers.
  • PURPOSE: To detect and quantify hypoxia in colorectal adenocarcinomas by use of pimonidazole and iododeoxyuridine (IdUrd) as extrinsic markers and carbonic anhydrase IX (CA IX), microvessel density (MVD), epidermal growth-factor receptor (EGFR), and vascular endothelial growth factor (VEGF) as intrinsic markers of hypoxia.
  • METHODS AND MATERIAL: Twenty patients with an adenocarcinoma of the left colon and rectum treated by primary surgery were injected with pimonidazole and IdUrd.
  • CONCLUSION: Chronic and acute hypoxic regions are present in colorectal tumors, as shown by pimonidazole and IdUrd staining.
  • [MeSH-major] Adenocarcinoma / physiopathology. Cell Hypoxia. Colonic Neoplasms / physiopathology. Rectal Neoplasms / physiopathology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IDOXURIDINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16618579.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Nitroimidazoles; 0 / Vascular Endothelial Growth Factor A; 46JO4D76R2 / pimonidazole; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 4.2.1.1 / Carbonic Anhydrases; LGP81V5245 / Idoxuridine
  •  go-up   go-down


62. Salepci T, Yazici H, Dane F, Topuz E, Dalay N, Onat H, Aykan F, Seker M, Aydiner A: Detection of human papillomavirus DNA by polymerase chain reaction and southern blot hybridization in colorectal cancer patients. J BUON; 2009 Jul-Sep;14(3):495-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of human papillomavirus DNA by polymerase chain reaction and southern blot hybridization in colorectal cancer patients.
  • PURPOSE: The molecular mechanisms related to colorectal carcinogenesis are controversial.
  • The purpose of this study was to evaluate the possible role of high-risk oncogenic human papillomavirus (HPV) types in the pathogenesis of colorectal cancer.
  • PATIENTS AND METHODS: Tumor, and corresponding normal mucosal tissue specimens were obtained soon after surgery from 56 patients with colorectal adenocarcinoma.
  • We studied both neoplastic and normal colon tissues for the presence of HPV types 6, 11, 16, 18, and 33.
  • RESULTS: HPV DNA was detected in 46 (82.14 %) of 56 colorectal adenocarcinomas and in 18 (32 %) of 56 normal colonic mucosal tissue samples.
  • CONCLUSION: Detection of HPV DNA types 18 and 33 in most of the colorectal adenocarcinoma specimens suggests that HPVs may be related to carcinogenesis in glandular cells of the colorectal mucosa of our patient population.
  • [MeSH-major] Adenocarcinoma / virology. Alphapapillomavirus / isolation & purification. Colorectal Neoplasms / virology. Human papillomavirus 18 / isolation & purification. Papillomavirus Infections / virology

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - HPV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19810144.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


63. Choi MG, Kim SW, Han SS, Jang JY, Park YH: High incidence of extrapancreatic neoplasms in patients with intraductal papillary mucinous neoplasms. Arch Surg; 2006 Jan;141(1):51-6; discussion 56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thirty-eight patients with mucinous cystic neoplasms and 50 patients with pancreatic ductal adenocarcinoma also were examined for development of extrapancreatic neoplasms.
  • MAIN OUTCOME MEASURES: The incidence and clinicopathological features of extrapancreatic neoplasms with IPMNs were compared with those with mucinous cystic neoplasm and pancreatic ductal adenocarcinoma.
  • Gastric adenocarcinoma (33%) and colorectal adenocarcinoma (17%) were the most common neoplasms in the 24 patients.
  • The incidence of extrapancreatic neoplasms in patients with IPMN was significantly higher than in those with other pancreatic diseases such as mucinous cystic neoplasm (8%) or pancreatic ductal adenocarcinoma (10%).
  • [MeSH-major] Adenocarcinoma, Mucinous / epidemiology. Carcinoma, Pancreatic Ductal / epidemiology. Carcinoma, Papillary / epidemiology. Neoplasms, Multiple Primary / epidemiology
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / epidemiology. Aged. Female. Humans. Incidence. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arch Surg. 2006 Jul;141(7):716-7; author reply 717 [16847252.001]
  • (PMID = 16415411.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Schottenfeld D, Beebe-Dimmer JL, Vigneau FD: The epidemiology and pathogenesis of neoplasia in the small intestine. Ann Epidemiol; 2009 Jan;19(1):58-69
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The epidemiology and pathogenesis of neoplasia in the small intestine.
  • PURPOSE: The mucosa of the small intestine encompasses about 90% of the luminal surface area of the digestive system, but only 2% of the total annual gastrointestinal cancer incidence in the United States.
  • METHODS: The remarkable contrast in age-standardized cancer incidence between the small and large intestine has been reviewed with respect to the cell type patterns, demographic features, and molecular characteristics of neoplasms.
  • RESULTS: Particularly noteworthy is the predominance of adenocarcinoma in the colon, which exceeds 98% of the total incidence by cell type, in contrast to that of 30% to 40% in the small intestine, resulting in an age-standardized ratio of rates exceeding 50-fold.
  • The positive correlation in global incidence rates of small and large intestinal neoplasms and the reciprocal increases in risk of second primary adenocarcinomas suggest that there are common environmental risk factors.
  • The pathophysiology of Crohn inflammatory bowel disease and the elevated risk of adenocarcinoma demonstrate the significance of the impaired integrity of the mucosal barrier and of aberrant immune responses to luminal indigenous and potentially pathogenic microorganisms.
  • CONCLUSION: In advancing a putative mechanism for the contrasting mucosal susceptibilities of the small and large intestine, substantial differences are underscored in the diverse taxonomy, concentration and metabolic activity of anaerobic organisms, rate of intestinal transit, changing pH, and the enterohepatic recycling and metabolism of bile acids.
  • Experimental and epidemiologic studies are cited that suggest that the changing microecology, particularly in the colon, is associated with enhanced metabolic activation of ingested and endogenously formed procarcinogenic substrates.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Immunol. 2002 Jan;2(1):37-45 [11905836.001]
  • [Cites] Gastroenterology. 2002 Apr;122(4):854-66 [11910336.001]
  • [Cites] Gut. 2002 May;50(5):647-52 [11950810.001]
  • [Cites] Hum Pathol. 2002 Mar;33(3):322-9 [11979373.001]
  • [Cites] Am J Gastroenterol. 2002 Jun;97(6):1421-8 [12094860.001]
  • [Cites] Gastroenterology. 2002 Nov;123(5):1428-35 [12404215.001]
  • [Cites] Lancet Oncol. 2003 Jan;4(1):22-9 [12517536.001]
  • [Cites] Ann N Y Acad Sci. 2004 Apr;1014:13-27 [15153416.001]
  • [Cites] Ann N Y Acad Sci. 2004 Apr;1014:199-208 [15153435.001]
  • [Cites] Ann N Y Acad Sci. 2004 Apr;1014:218-9 [15153437.001]
  • [Cites] Ann Surg. 2004 Jul;240(1):117-22 [15213627.001]
  • [Cites] Cancer Res. 1974 Sep;34(9):2368-72 [4843537.001]
  • [Cites] Clin Gastroenterol. 1977 Jan;6(1):3-24 [330051.001]
  • [Cites] Am J Surg. 1978 Jan;135(1):86-90 [623378.001]
  • [Cites] Cancer Res. 1981 Apr;41(4):1363-7 [7194137.001]
  • [Cites] Dis Colon Rectum. 1987 Oct;30(10):790-9 [3308369.001]
  • [Cites] Cancer. 1989 Nov 15;64(10):2178-83 [2804907.001]
  • [Cites] J Natl Cancer Inst. 1990 Apr 18;82(8):650-61 [2157027.001]
  • [Cites] Mutat Res. 1990 May;238(3):313-20 [2188127.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Aug;8(8):715-9 [10744132.001]
  • [Cites] Cancer Lett. 2000 Oct 16;159(1):73-8 [10974408.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 1;92(21):1740-52 [11058617.001]
  • [Cites] Cancer Causes Control. 2000 Oct;11(9):791-7 [11075867.001]
  • [Cites] Gastroenterology. 2000 Dec;119(6):1447-53 [11113065.001]
  • [Cites] Cancer Causes Control. 2001 Jan;12(1):13-21 [11227921.001]
  • [Cites] Int J Biochem Cell Biol. 2001 Feb;33(2):193-203 [11240376.001]
  • [Cites] Int J Cancer. 1999 Jul 19;82(2):171-4 [10389747.001]
  • [Cites] Am J Gastroenterol. 1999 Aug;94(8):2010-6 [10445521.001]
  • [Cites] Am J Gastroenterol. 1999 Aug;94(8):2128-34 [10445539.001]
  • [Cites] Fed Proc. 1964 Nov-Dec;23:1386-8 [14236160.001]
  • [Cites] Am J Gastroenterol. 2005 Jan;100(1):162-8 [15654796.001]
  • [Cites] Gastroenterology. 2005 Mar;128(3):590-9 [15765394.001]
  • [Cites] Nat Rev Cancer. 2005 Apr;5(4):251-62 [15803153.001]
  • [Cites] Gastroenterology. 2005 Apr;128(4 Suppl 1):S47-51 [15825126.001]
  • [Cites] Gastroenterology. 2005 Apr;128(4 Suppl 1):S57-67 [15825128.001]
  • [Cites] Am J Gastroenterol. 2005 May;100(5):1134-42 [15842590.001]
  • [Cites] Nat Rev Genet. 2005 May;6(5):376-88 [15861209.001]
  • [Cites] Cell Mol Life Sci. 2005 Apr;62(7-8):791-9 [15868404.001]
  • [Cites] Gastroenterol Clin North Am. 2005 Sep;34(3):401-12, vii-viii [16084304.001]
  • [Cites] Gastroenterol Clin North Am. 2005 Sep;34(3):437-50, viii [16084306.001]
  • [Cites] Cancer Causes Control. 2005 Sep;16(7):781-7 [16132788.001]
  • [Cites] Br J Cancer. 2005 Oct 3;93(7):807-10 [16175183.001]
  • [Cites] Int J Cancer. 2006 Jan 1;118(1):189-96 [16003748.001]
  • [Cites] Ann Intern Med. 2005 Dec 20;143(12):895-904 [16365470.001]
  • [Cites] Am J Gastroenterol. 2005 Dec;100(12):2724-9 [16393226.001]
  • [Cites] Annu Rev Med. 2006;57:207-21 [16409146.001]
  • [Cites] Lancet Oncol. 2006 Feb;7(2):149-56 [16455479.001]
  • [Cites] Hum Mol Genet. 2006 Mar 15;15(6):1015-23 [16461335.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):69-83 [16514135.001]
  • [Cites] Clin Microbiol Rev. 2006 Apr;19(2):315-37 [16614252.001]
  • [Cites] Gastroenterology. 2006 Apr;130(4):1039-46 [16618397.001]
  • [Cites] Lancet. 2006 Apr 15;367(9518):1271-84 [16631883.001]
  • [Cites] J Natl Cancer Inst. 2006 Jul 5;98(13):920-31 [16818856.001]
  • [Cites] J Natl Cancer Inst. 2006 Jul 5;98(13):936-9 [16818858.001]
  • [Cites] Gastroenterol Clin North Am. 2006 Sep;35(3):621-39 [16952744.001]
  • [Cites] Lab Invest. 2006 Oct;86(10):1052-63 [16909128.001]
  • [Cites] J Natl Cancer Inst. 2006 Sep 20;98(18):1321-30 [16985251.001]
  • [Cites] Ann N Y Acad Sci. 2006 Aug;1072:9-18 [17057186.001]
  • [Cites] Ann N Y Acad Sci. 2006 Aug;1072:135-54 [17057196.001]
  • [Cites] Ann N Y Acad Sci. 2006 Aug;1072:321-31 [17057212.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Nov;15(11):2069-77 [17119030.001]
  • [Cites] Carcinogenesis. 2007 Jan;28(1):215-22 [16887864.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2551-7 [17167138.001]
  • [Cites] World J Gastroenterol. 2007 Jan 7;13(1):146-51 [17206762.001]
  • [Cites] Annu Rev Med. 2007;58:401-16 [16987083.001]
  • [Cites] Cancer. 2007 Jun 15;109(12):2420-31 [17469181.001]
  • [Cites] Nat Rev Cancer. 2007 Aug;7(8):599-612 [17646865.001]
  • [Cites] Int J Cancer. 2007 Dec 1;121(11):2381-6 [17893868.001]
  • [Cites] Clin Microbiol Rev. 2007 Oct;20(4):593-621 [17934076.001]
  • [Cites] Gastroenterol Clin North Am. 2007 Sep;36(3):499-513, vii [17950435.001]
  • [Cites] Gastroenterol Clin North Am. 2007 Dec;36(4):927-46, viii [17996798.001]
  • [Cites] Annu Rev Pathol. 2007;2:401-29 [18039105.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2533-47 [18086756.001]
  • [Cites] Gastroenterology. 2008 Jan;134(1):306-23 [18166359.001]
  • [Cites] Lancet Oncol. 2008 Jan;9(1):61-72 [18177818.001]
  • [Cites] Am J Gastroenterol. 2008 Jan;103(1):190-5 [18184122.001]
  • [Cites] Gastroenterology. 2008 Feb;134(2):388-95 [18242207.001]
  • [Cites] Gastroenterology. 2008 Feb;134(2):577-94 [18242222.001]
  • [Cites] Br J Cancer. 2008 Feb 26;98(4):684-8 [18253129.001]
  • [Cites] J Surg Oncol. 2008 Mar 15;97(4):350-9 [18286477.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Cancer Causes Control. 2002 Feb;13(1):27-34 [11899115.001]
  • [Cites] JAMA. 2002 Mar 20;287(11):1413-9 [11903028.001]
  • [Cites] Gut. 2001 Apr;48(4):526-35 [11247898.001]
  • [Cites] Gut. 2001 Apr;48(4):536-41 [11247899.001]
  • [Cites] Hum Mol Genet. 2001 Apr;10(7):721-33 [11257105.001]
  • [Cites] Glycobiology. 2001 Feb;11(2):1R-10R [11287395.001]
  • [Cites] Am J Pathol. 2001 May;158(5):1803-8 [11337378.001]
  • [Cites] Nature. 2001 May 31;411(6837):599-603 [11385576.001]
  • [Cites] Gastroenterology. 2001 Sep;121(3):542-7 [11522737.001]
  • [Cites] Am J Pathol. 2001 Dec;159(6):2017-22 [11733352.001]
  • [Cites] Annu Rev Pathol. 2008;3:557-86 [18039140.001]
  • [Cites] Int J Cancer. 2008 Aug 15;123(4):867-73 [18491401.001]
  • [Cites] Gut. 2002 Feb;50(2):218-23 [11788563.001]
  • [Cites] Oncogene. 2002 Jan 3;21(1):158-64 [11791187.001]
  • [Cites] Arch Pharm Res. 2001 Dec;24(6):564-7 [11794536.001]
  • [Cites] Lancet. 2002 Jan 5;359(9300):62-9 [11809204.001]
  • [Cites] Am J Hum Genet. 2002 Apr;70(4):845-57 [11875755.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Mar;7(3):243-51 [9521441.001]
  • [Cites] Am J Epidemiol. 1998 May 15;147(10):903-10 [9596467.001]
  • [Cites] Gastroenterology. 2002 Jan;122(1):44-54 [11781279.001]
  • [Cites] Dis Colon Rectum. 2002 Jan;45(1):91-7 [11786770.001]
  • [Cites] Lancet. 2003 Feb 8;361(9356):512-9 [12583961.001]
  • [Cites] Lancet. 2003 Apr 12;361(9365):1290-2 [12699968.001]
  • [Cites] Arch Intern Med. 2003 Jul 14;163(13):1566-72 [12860579.001]
  • [Cites] Lancet. 2003 Aug 2;362(9381):383-91 [12907013.001]
  • [Cites] Am J Med. 2003 Aug 15;115(3):191-5 [12935825.001]
  • [Cites] Surg Oncol. 2003 Aug;12(2):153-72 [12946486.001]
  • [Cites] Int J Cancer. 2003 Nov 1;107(2):171-6 [12949790.001]
  • [Cites] Am J Clin Nutr. 2003 Oct;78(4):675-83 [14522724.001]
  • [Cites] N Engl J Med. 2004 Jan 15;350(3):239-48 [14724303.001]
  • [Cites] Cancer. 2004 Feb 1;100(3):524-30 [14745868.001]
  • [Cites] J Nutr. 2004 Feb;134(2):459-64 [14747689.001]
  • [Cites] Cancer Causes Control. 2004 Feb;15(1):35-43 [14970733.001]
  • [Cites] Ann N Y Acad Sci. 2004 Apr;1014:1-12 [15153415.001]
  • [Cites] Cancer. 1990 Aug 15;66(4):702-15 [2167140.001]
  • [Cites] Br J Cancer. 1991 Jan;63(1):143-5 [1989654.001]
  • [Cites] Surg Gynecol Obstet. 1991 Nov;173(5):343-9 [1948581.001]
  • [Cites] Gastroenterology. 1992 Jun;102(6):1980-2 [1316858.001]
  • [Cites] Gut. 1992 Sep;33(9):1239-45 [1427378.001]
  • [Cites] Nutr Cancer. 1992;18(2):97-111 [1437657.001]
  • [Cites] Cancer Causes Control. 1993 Mar;4(2):163-9 [8481495.001]
  • [Cites] Dis Colon Rectum. 1993 Jul;36(7):654-61 [8348849.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1993 Nov-Dec;2(6):551-3 [8268772.001]
  • [Cites] Br J Surg. 1994 Jan;81(1):20-4 [8313111.001]
  • [Cites] Am J Gastroenterol. 1994 May;89(5):699-701 [8172140.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1994 Apr-May;3(3):205-7 [8019367.001]
  • [Cites] Gut. 1994 Aug;35(8):1090-7 [7926912.001]
  • [Cites] Br J Surg. 1994 Dec;81(12):1722-33 [7827926.001]
  • [Cites] Scand J Gastroenterol. 1996 Apr;31(4):376-82 [8726307.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Feb;5(2):81-4 [8850266.001]
  • [Cites] Int J Epidemiol. 1996 Aug;25(4):722-8 [8921448.001]
  • [Cites] Int J Cancer. 1997 Mar 4;70(5):512-7 [9052748.001]
  • [Cites] Cancer Res. 1997 Mar 15;57(6):1098-102 [9067278.001]
  • [Cites] Cancer. 1997 May 1;79(9):1804-8 [9128999.001]
  • [Cites] Gastroenterology. 1997 Jul;113(1):127-35 [9207270.001]
  • [Cites] Ann Intern Med. 1997 Sep 15;127(6):423-8 [9312998.001]
  • [Cites] Nat Genet. 1998 Jan;18(1):38-43 [9425897.001]
  • [Cites] Ann Intern Med. 1998 Jun 1;128(11):896-9 [9634427.001]
  • [Cites] Cancer. 1998 Jul 15;83(2):240-4 [9669805.001]
  • [Cites] J Pathol. 1998 Jun;185(2):119-22 [9713336.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5267-70 [9850045.001]
  • [Cites] Am J Clin Nutr. 1999 Mar;69(3):354-65 [10075317.001]
  • [Cites] Cancer. 1999 Apr 15;85(8):1664-9 [10223558.001]
  • [Cites] Am J Gastroenterol. 1999 May;94(5):1139-52 [10235185.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Dec;8(12):1101-5 [10613343.001]
  • [Cites] Cancer Causes Control. 2000 Feb;11(2):145-50 [10710198.001]
  • (PMID = 19064190.001).
  • [ISSN] 1873-2585
  • [Journal-full-title] Annals of epidemiology
  • [ISO-abbreviation] Ann Epidemiol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K07 CA127214; United States / NCI NIH HHS / CA / N01PC35145; United States / NCI NIH HHS / CA / 1K07CA127214-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines
  • [Number-of-references] 151
  • [Other-IDs] NLM/ NIHMS521424; NLM/ PMC3792582
  •  go-up   go-down


65. Kaminska J, Nowacki MP, Kowalska M, Rysinska A, Chwalinski M, Fuksiewicz M, Michalski W, Chechlinska M: Clinical significance of serum cytokine measurements in untreated colorectal cancer patients: soluble tumor necrosis factor receptor type I--an independent prognostic factor. Tumour Biol; 2005 Jul-Aug;26(4):186-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of serum cytokine measurements in untreated colorectal cancer patients: soluble tumor necrosis factor receptor type I--an independent prognostic factor.
  • The aim of this study was to exploit the potential clinical use of circulating cytokine measurements in colorectal cancer (CRC) patients.
  • All tumors were verified histologically as colorectal adenocarcinomas and staged according to TNM classification.
  • The levels of circulating interleukin (IL)-6, IL-8, macrophage colony-stimulating factor (M-CSF) and interleukin 1 receptor antagonist (IL-1ra) significantly increased with the clinical stage of CRC, and the levels of IL-6, soluble tumor necrosis factor (sTNF) receptor type I (RI), soluble interleukin 2 receptor alpha and TNFalpha with tumor grade, while IL-6, IL-8, M-CSF, IL-1ra and sTNF RI levels significantly rose with bowel wall invasion.
  • None of the cytokine or soluble cytokine receptor levels were influenced by age, gender and colon versus rectum localization. sTNF RI, IL-8, IL-6 and vascular endothelial growth factor measurements demonstrated the highest diagnostic sensitivity. sTNF RI was found elevated in the greatest percentage of all CRC patients, in the greatest proportion of stage I patients and presented the best diagnostic sensitivity.
  • [MeSH-major] Biomarkers, Tumor / blood. Colorectal Neoplasms / blood. Colorectal Neoplasms / pathology. Receptors, Tumor Necrosis Factor, Type I / blood

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 S. Karger AG, Basel.
  • (PMID = 16006772.001).
  • [ISSN] 1010-4283
  • [Journal-full-title] Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  • [ISO-abbreviation] Tumour Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cytokines; 0 / Receptors, Cytokine; 0 / Receptors, Tumor Necrosis Factor, Type I
  •  go-up   go-down


66. Gazzaniga A, Maroni A, Foppoli A, Palugan L: Oral colon delivery: rationale and time-based drug design strategy. Discov Med; 2006 Dec;6(36):223-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral colon delivery: rationale and time-based drug design strategy.
  • Increasing efforts have recently been spent onto the accomplishment of oral colon targeting.
  • Indeed, this has been related to a number of local as well as systemic highly interesting applications, such as a more effective and tolerable therapy of inflammatory bowel disease (IBD), the pharmacological prevention of colorectal adenocarcinoma, and a possible improvement in the oral bioavailability of peptide and protein drugs.
  • For the purpose of colon targeting, a variety of delivery technologies have been described, which rely on typical variation patterns shown by selected physiological parameters throughout the gastrointestinal tract.
  • [MeSH-major] Colon / metabolism. Colon / pathology. Drug Delivery Systems / methods. Drug Design. Pharmaceutical Preparations / administration & dosage

  • MedlinePlus Health Information. consumer health - Medicines.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17250787.001).
  • [ISSN] 1944-7930
  • [Journal-full-title] Discovery medicine
  • [ISO-abbreviation] Discov Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Pharmaceutical Preparations
  •  go-up   go-down


67. Ribeiro ML, Priolli DG, Miranda DD, Arçari DP, Pedrazzoli J Jr, Martinez CA: Analysis of oxidative DNA damage in patients with colorectal cancer. Clin Colorectal Cancer; 2008 Jul;7(4):267-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of oxidative DNA damage in patients with colorectal cancer.
  • PURPOSE: The aim of this study was to measure the levels of oxidative DNA damage in cells isolated from the colon mucosa in patients with colorectal cancer and to compare normal and neoplastic tissues and make correlations with anatomopathologic variables.
  • PATIENTS AND METHODS: Thirty-three patients with colorectal adenocarcinoma were studied.
  • The cells isolated from the neoplastic mucosal tissue of the colon presented significantly greater mean extent of DNA strand breakage than the cells isolated from normal tissue.
  • CONCLUSION: Assessment of the levels of oxidative damage at the different stages of colorectal carcinogenesis is of great interest because it enables evaluation of the effectiveness of antioxidant substances that could be used as preventive measures against the initial oxidative aggressive action on the colonic mucosa.
  • [MeSH-major] Colorectal Neoplasms / genetics. DNA Damage. Intestinal Mucosa / pathology. Oxidative Stress
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Aged. Antioxidants / therapeutic use. Comet Assay. Female. Humans. Male. Middle Aged. Neoplasm Staging. Oligonucleotide Array Sequence Analysis. Reactive Oxygen Species / metabolism

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18650195.001).
  • [ISSN] 1533-0028
  • [Journal-full-title] Clinical colorectal cancer
  • [ISO-abbreviation] Clin Colorectal Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Reactive Oxygen Species
  •  go-up   go-down


68. Zhao ZR, Zhang ZY, Cui DS, Jiang L, Zhang HJ, Wang MW, Sun XF: Particularly interesting new cysteine-histidine rich protein expression in colorectal adenocarcinomas. World J Gastroenterol; 2006 Jan 14;12(2):298-301
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Particularly interesting new cysteine-histidine rich protein expression in colorectal adenocarcinomas.
  • AIM: To study the relationship between particularly interesting new cysteine-histidine rich protein (PINCH) expression and clinicopathological factors in Chinese colorectal cancer patients.
  • METHODS: The expression of PINCH was examined by immumohistochemistry in 141 samples of primary colorectal adenocarcinoma and 92 normal samples of colorectal mucosa.
  • CONCLUSION: The expression of PINCH was upregulated in colorectal cancers, and especially at the margin of tumours, and further was related to mucinous and signet-ring cell carcinomas.
  • The results suggest that expression of PINCH may be involved in the tumourigenesis and aggressiveness of colorectal cancers.
  • [MeSH-major] Adenocarcinoma / chemistry. Colorectal Neoplasms / chemistry. DNA-Binding Proteins / analysis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2000 Jul 28;275(30):22607-10 [10801899.001]
  • [Cites] Neoplasia. 2004 Nov-Dec;6(6):796-801 [15720806.001]
  • [Cites] Cancer. 2002 Sep 15;95(6):1387-95 [12216108.001]
  • [Cites] Glia. 2003 Feb;41(3):213-23 [12528177.001]
  • [Cites] Cancer. 1976 Apr;37(4):1891-1900 [177180.001]
  • [Cites] Adv Cancer Res. 1988;50:159-96 [3287842.001]
  • [Cites] Cancer Res. 1991 Aug 15;51(16):4436-42 [1868464.001]
  • [Cites] Int J Cancer. 1991 Sep 9;49(2):220-3 [1652568.001]
  • [Cites] J Surg Oncol. 1992 Sep;51(1):60-4 [1325577.001]
  • [Cites] Am J Gastroenterol. 1994 May;89(5):665-9 [8172135.001]
  • [Cites] Am J Clin Pathol. 1996 May;105(5):604-12 [8623770.001]
  • [Cites] Cancer Lett. 1996 Jun 5;103(2):163-70 [8635153.001]
  • [Cites] Annu Rev Cell Dev Biol. 1995;11:379-416 [8689563.001]
  • [Cites] Annu Rev Cell Dev Biol. 1995;11:549-99 [8689569.001]
  • [Cites] J Pathol. 1996 May;179(1):15-9 [8691338.001]
  • [Cites] Am J Gastroenterol. 1996 Oct;91(10):2195-9 [8855747.001]
  • [Cites] Annu Rev Cell Dev Biol. 1996;12:463-518 [8970735.001]
  • [Cites] J Pathol. 1997 Aug;182(4):380-4 [9306957.001]
  • [Cites] Mol Biol Cell. 1998 Dec;9(12):3367-82 [9843575.001]
  • [Cites] J Cell Biol. 1999 Jan 11;144(1):45-57 [9885243.001]
  • [Cites] Mol Cell Biol. 1999 Mar;19(3):2425-34 [10022929.001]
  • [Cites] Int J Oncol. 1999 Jun;14(6):1057-61 [10339657.001]
  • [Cites] J Biol Chem. 2001 Feb 16;276(7):4932-9 [11078733.001]
  • (PMID = 16482633.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / DNA-Binding Proteins; 0 / LIM Domain Proteins; 0 / LIMS1 protein, human; 0 / Membrane Proteins
  • [Other-IDs] NLM/ PMC4066042
  •  go-up   go-down


69. Frederiksen BL, Osler M, Harling H, Danish Colorectal Cancer Group, Jørgensen T: Social inequalities in stage at diagnosis of rectal but not in colonic cancer: a nationwide study. Br J Cancer; 2008 Feb 12;98(3):668-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Social inequalities in stage at diagnosis of rectal but not in colonic cancer: a nationwide study.
  • We investigated stage at diagnosis in relation to socioeconomic status (SES) among 15 274 patients with colorectal adenocarcinoma diagnosed in 1996-2004 nationwide in Denmark.
  • No social gradient was found among colon cancer patients.
  • The social gradient found in rectal cancer patients was significantly different from the lack of association found among colon cancer patients.
  • [MeSH-major] Colonic Neoplasms / diagnosis. Colonic Neoplasms / pathology. Rectal Neoplasms / diagnosis. Rectal Neoplasms / pathology. Social Class

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Med Screen. 2002;9(3):104-8 [12370320.001]
  • [Cites] J Epidemiol Community Health. 2006 Sep;60(9):804-10 [16905727.001]
  • [Cites] Scand J Public Health. 2003;31(2):126-36 [12745763.001]
  • [Cites] Public Health. 2003 Nov;117(6):389-95 [14522153.001]
  • [Cites] Ugeskr Laeger. 2004 Jan 26;166(5):368-71 [15017731.001]
  • [Cites] CMAJ. 2004 Aug 31;171(5):461-5 [15337726.001]
  • [Cites] Soc Sci Med. 1992 Apr;34(8):907-17 [1604380.001]
  • [Cites] Cancer. 1992 Jul 15;70(2):402-9 [1617590.001]
  • [Cites] Jpn J Clin Oncol. 1992 Aug;22(4):270-7 [1434026.001]
  • [Cites] Cancer. 1993 Aug 15;72(4):1165-70 [8339209.001]
  • [Cites] J Epidemiol Community Health. 1993 Jun;47(3):229-31 [8350037.001]
  • [Cites] Br J Cancer. 1996 Sep;74(6):985-8 [8826871.001]
  • [Cites] Cancer. 2006 Sep 1;107(5 Suppl):1121-7 [16802324.001]
  • [Cites] Cancer. 2006 Sep 1;107(5 Suppl):1189-95 [16835910.001]
  • [Cites] Colorectal Dis. 2006 Oct;8(8):688-95 [16970580.001]
  • [Cites] Cancer Detect Prev. 2006;30(4):341-6 [16965875.001]
  • [Cites] Am J Public Health. 1996 Dec;86(12):1794-7 [9003140.001]
  • [Cites] J Public Health Med. 1997 Sep;19(3):288-94 [9347452.001]
  • [Cites] Gerontologist. 1998 Oct;38(5):618-27 [9803650.001]
  • [Cites] BMJ. 1999 Oct 9;319(7215):1003-4 [10514175.001]
  • [Cites] J Epidemiol Community Health. 2006 Jan;60(1):7-12 [16361448.001]
  • [Cites] Aust N Z J Public Health. 2006 Feb;30(1):64-70 [16502954.001]
  • [Cites] J Epidemiol Community Health. 2003 Apr;57(4):301-9 [12646548.001]
  • (PMID = 18231103.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2243153
  •  go-up   go-down


70. Mól W, Matyja M, Filip B, Wietrzyk J, Boryczka S: Synthesis and antiproliferative activity in vitro of novel (2-butynyl)thioquinolines. Bioorg Med Chem; 2008 Sep 1;16(17):8136-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The series of new acetylenic thioquinolines containing propargyl, 2-butynyl, 4-bromo-2-butynyl, and 4-hydroxy-2-butynyl groups has been prepared and tested for antiproliferative activity in vitro against human [SW707 (colorectal adenocarcinoma), CCRF/CEM (leukemia)] and murine [P388 (leukemia), B16 (melanoma)] cancer lines.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / chemical synthesis. Antineoplastic Agents / pharmacology. Colorectal Neoplasms / drug therapy. Leukemia, Experimental / drug therapy. Melanoma, Experimental / drug therapy. Quinolines / pharmacology. Sulfides / pharmacology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18682326.001).
  • [ISSN] 1464-3391
  • [Journal-full-title] Bioorganic & medicinal chemistry
  • [ISO-abbreviation] Bioorg. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinolines; 0 / Sulfides
  •  go-up   go-down


71. Ballian N, Liu SH, Brunicardi FC: Transcription factor PDX-1 in human colorectal adenocarcinoma: a potential tumor marker? World J Gastroenterol; 2008 Oct 14;14(38):5823-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcription factor PDX-1 in human colorectal adenocarcinoma: a potential tumor marker?
  • AIM: To examine the expression of pancreatic duodenal homeobox-1 (PDX-1) transcription factor in human colorectal cancer.
  • METHODS: RT-PCR, Western blotting, and immuno-histochemistry were performed to determine the expression pattern of transcription factor PDX-1 in primary colorectal tumor, hepatic metastasis, and benign colon tissue from a single patient.
  • Lower levels of PDX-1 were found to be present in the primary tumor, while normal colon tissue failed to express detectable levels of PDX-1.
  • Immunohistochemistry confirmed high metastasis PDX-1 expression, lower levels in the primary tumor, and the presence of only traces of PDX-1 in normal colon tissue.
  • CONCLUSION: These data argue for further evaluation of PDX-1 as a biomarker for colorectal cancer.
  • [MeSH-major] Adenocarcinoma / chemistry. Biomarkers, Tumor / analysis. Colorectal Neoplasms / chemistry. Homeodomain Proteins / analysis. Liver Neoplasms / chemistry. Trans-Activators / analysis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pol J Pathol. 2004;55(3):9-14 [15619975.001]
  • [Cites] Diabetes. 1999 May;48(5):1013-9 [10331405.001]
  • [Cites] World J Surg. 2005 Mar;29(3):334-8 [15706433.001]
  • [Cites] J Womens Health (Larchmt). 2007 Jan-Feb;16(1):57-65 [17324097.001]
  • [Cites] Histochem Cell Biol. 2007 Nov;128(5):445-55 [17851679.001]
  • [Cites] J Surg Res. 2008 Jan;144(1):8-16 [17583748.001]
  • [Cites] Gastroenterol Clin North Am. 2008 Mar;37(1):97-115, vii [18313542.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Gastroenterology. 2008 May;134(5):1570-95 [18384785.001]
  • [Cites] Pancreas. 2008 Aug;37(2):210-20 [18665085.001]
  • [Cites] N Engl J Med. 2000 Jul 20;343(3):169-74 [10900275.001]
  • [Cites] N Engl J Med. 2000 Nov 30;343(22):1603-7 [11096167.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):1065-70 [11158595.001]
  • [Cites] Clin Cancer Res. 2001 May;7(5):1118-26 [11350874.001]
  • [Cites] Gut. 2002 Sep;51(3):450-4 [12171973.001]
  • [Cites] Surgery. 2003 Aug;134(2):260-6 [12947327.001]
  • [Cites] Pancreas. 2004 Mar;28(2):109-20 [15028942.001]
  • [Cites] World J Surg. 2004 Aug;28(8):826-33 [15457366.001]
  • [Cites] N Engl J Med. 1993 May 13;328(19):1365-71 [8474513.001]
  • [Cites] J Biol Chem. 1994 May 27;269(21):15229-37 [7910823.001]
  • [Cites] Am J Pathol. 1995 Sep;147(3):586-92 [7677172.001]
  • [Cites] Genomics. 1996 Jun 1;34(2):270-1 [8661069.001]
  • [Cites] Lancet. 1996 Nov 30;348(9040):1467-71 [8942774.001]
  • [Cites] Lancet. 1996 Nov 30;348(9040):1472-7 [8942775.001]
  • [Cites] Drugs. 1997 Apr;53(4):593-607 [9098662.001]
  • [Cites] Diabetes. 1999 Mar;48(3):507-13 [10078550.001]
  • [Cites] N Engl J Med. 2005 Feb 3;352(5):476-87 [15689586.001]
  • (PMID = 18855980.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Homeodomain Proteins; 0 / RNA, Messenger; 0 / Trans-Activators; 0 / pancreatic and duodenal homeobox 1 protein
  • [Other-IDs] NLM/ PMC2751891
  •  go-up   go-down


72. Zumkeller N, Brenner H, Chang-Claude J, Hoffmeister M, Nieters A, Rothenbacher D: Helicobacter pylori infection, interleukin-1 gene polymorphisms and the risk of colorectal cancer: evidence from a case-control study in Germany. Eur J Cancer; 2007 May;43(8):1283-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Helicobacter pylori infection, interleukin-1 gene polymorphisms and the risk of colorectal cancer: evidence from a case-control study in Germany.
  • A positive association with colorectal cancer has also been suggested, but available evidence remains inconclusive.
  • In this population-based case-control study we investigated the association between H. pylori seroprevalence and colorectal adenocarcinoma under consideration of pro-inflammatory gene polymorphisms (384 incident cancer patients, 467 matched control subjects).
  • Overall, the H. pylori seroprevalence was higher among cases (51%) than among controls (44%), and a positive association between H. pylori seroprevalence and colorectal adenocarcinoma risk was found, that persisted after adjustment for known potential confounders, including measures of socioeconomic status (odds ratio (OR)=1.41; 95% confidence intervals (CI), 1.06-1.87).
  • Additionally, a pro-inflammatory genotype did not increase the colorectal cancer risk associated with H. pylori infection. H. pylori positive subjects carrying the pro-inflammatory genotypes even had a lower risk.
  • [MeSH-major] Adenocarcinoma / etiology. Colorectal Neoplasms / etiology. Helicobacter Infections / complications. Helicobacter pylori. Interleukin-1 / genetics. Polymorphism, Genetic / genetics


73. Rupert K, Holubec L, Nosek J, Houdek K, Topolcan O, Treska V: [Significance of the TPS cytokeratin marker in the postoperative follow up of colorectal carcinoma patients]. Rozhl Chir; 2009 Aug;88(8):428-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Significance of the TPS cytokeratin marker in the postoperative follow up of colorectal carcinoma patients].
  • AIM: Examination of tumour markers conducive to follow up of the patients with colorectal carcinoma.
  • MATERIAL AND METHODS: The tumour markers were examined in the population of patients with primarily established and histologically verified colorectal adenocarcinoma.
  • CONCLUSION: However, TPS seems to be a promising marker for the follow up of the patients with colorectal carcinoma.
  • [MeSH-major] Adenocarcinoma / surgery. Biomarkers, Tumor / analysis. Colorectal Neoplasms / surgery. Keratin-18 / analysis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20055296.001).
  • [ISSN] 0035-9351
  • [Journal-full-title] Rozhledy v chirurgii : měsíčník Československé chirurgické společnosti
  • [ISO-abbreviation] Rozhl Chir
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen; 0 / Keratin-18
  •  go-up   go-down


74. Khalifa MA, Rowsell CH, Gladdy R, Ko YJ, Hanna S, Smith A, Law C: Is EGFR expression altered following postoperative chemotherapy for colorectal adenocarcinoma? World J Surg Oncol; 2006;4:92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is EGFR expression altered following postoperative chemotherapy for colorectal adenocarcinoma?
  • BACKGROUND: There is immunohistochemical evidence to suggest that expression of epidermal growth factor receptor (EGFR) in primary colorectal adenocarcinoma predicts its expression in recurrent disease.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2000 May;6(5):2053-63 [10815932.001]
  • [Cites] Crit Rev Oncol Hematol. 1995 Jul;19(3):183-232 [7612182.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):903-13 [14967450.001]
  • [Cites] J Clin Oncol. 2004 Apr 1;22(7):1201-8 [14993230.001]
  • [Cites] Cancer Treat Rev. 2004 May;30(3):255-68 [15059649.001]
  • [Cites] J Histochem Cytochem. 2004 Jul;52(7):893-901 [15208356.001]
  • [Cites] N Engl J Med. 2004 Jul 22;351(4):337-45 [15269313.001]
  • [Cites] J Clin Oncol. 2004 Dec 1;22(23):4772-8 [15570078.001]
  • [Cites] J Clin Oncol. 2004 Dec 15;22(24):4966-70 [15611511.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):1803-10 [15677699.001]
  • [Cites] Ann Oncol. 2005 Sep;16(9):1503-7 [15980160.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7480-9 [16243822.001]
  • [Cites] J Biol Chem. 1990 May 15;265(14):7709-12 [2186024.001]
  • [Cites] Cancer Res. 1986 Sep;46(9):4726-31 [3015394.001]
  • [Cites] Clin Cancer Res. 2000 Dec;6(12):4885-92 [11156248.001]
  • (PMID = 17163999.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1705809
  •  go-up   go-down


75. Selvindos PB, Ho YH: Multimedia article. Laparoscopic ultralow anterior resection with colonic J-pouch-anal anastomosis. Dis Colon Rectum; 2008 Nov;51(11):1710-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Optimal treatment of mid to distal rectal cancers includes total mesorectal excision for oncologic clearance and, where reanastomosis is feasible, a colonic J-pouch-anal anastomosis improves bowel function.
  • Patients with adenocarcinoma underwent preoperative endorectal ultrasound to individualize for neoadjuvant chemoradiotherapy, based on local extent and lymph nodes seen.
  • Bowel continuity was restored by an intracoporeal double-cross stapled colonic J-pouch-anal anastomosis, but where not possible a coloplasty with pull-through handsewn coloanal anastomosis was performed.
  • The indications were adenocarcinoma (n = 51), squamous-cell carcinoma of rectum (n = 1), dermoid tumor of mesorectum (n = 1), large villous adenoma (n = 1), and carcinoid with local lymph node metastases (n = 1).
  • The adenocarcinomas were a median distance of 6 (3-12) cm from the anal verge.
  • The histologic grading or the adenocarcinoma patients were: Stage I, n = 14; Stage II, n = 23; Stage III, n = 11; Stage IV, n = 3.
  • At a median follow-up of 14 (2-33) months, none of the adenocarcinoma patients who had undergone curative resection had recurrences.
  • Four patients (8 percent) had postoperative complications that required operative/invasive intervention (anatomotic leak n = 1, proximal bowel ischemia n = 1, port site hernia n = 1, pelvic collection n = 1).
  • The ileostomy had been closed in 50 patients, and at last follow-up, the median stool frequency was two (1-8) bowel movements per day.
  • Further randomized, controlled studies that include assessing five-year cancer survival/recurrence, pelvic nerve dysfunction, and bowel function are needed before laparoscopic ultralow anterior resection becomes widely accepted.
  • [MeSH-major] Adenocarcinoma / surgery. Anal Canal / surgery. Colonic Pouches. Laparoscopy / methods. Proctocolectomy, Restorative / methods. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18679748.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Interactive Tutorial
  • [Publication-country] United States
  •  go-up   go-down


76. Bayley A, Rosewall T, Craig T, Bristow R, Chung P, Gospodarowicz M, Ménard C, Milosevic M, Warde P, Catton C: Clinical application of high-dose, image-guided intensity-modulated radiotherapy in high-risk prostate cancer. Int J Radiat Oncol Biol Phys; 2010 Jun 1;77(2):477-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To report the feasibility and early toxicity of dose-escalated image-guided IMRT to the pelvic lymph nodes (LN), prostate (P), and seminal vesicles (SV).
  • Clinical target volumes (CTVs) were delineated using computed tomography/magnetic resonance co-registration and included the prostate, portions of the SV, and the LN.
  • Planning target volume margins (PTV) used were as follows: P (10 mm, 7 mm posteriorly), SV (10 mm), and LN (5 mm).
  • Organs at risk (OaR) were the rectal and bladder walls, femoral heads, and large and small bowel.
  • Dose reductions were caused by small bowel and rectal wall constraints.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Lymphatic Irradiation / methods. Prostatic Neoplasms / radiotherapy. Radiotherapy, Intensity-Modulated / methods

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 19733014.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Antineoplastic Agents, Hormonal
  •  go-up   go-down


77. Owens SR, Greenson JK: Immunohistochemical staining for p63 is useful in the diagnosis of anal squamous cell carcinomas. Am J Surg Pathol; 2007 Feb;31(2):285-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical staining for p63 is useful in the diagnosis of anal squamous cell carcinomas.
  • By far, the most common carcinoma in this site is squamous cell carcinoma, but the differential diagnosis typically includes poorly differentiated adenocarcinoma and well-differentiated neuroendocrine carcinoma or carcinoid tumor.
  • However, accurate diagnosis is imperative, because the treatment differs between squamous carcinoma (chemoradiation) and the other types of carcinoma (surgical therapy).
  • Therefore, we undertook to ascertain its usefulness in the diagnosis of squamous carcinomas in the anal canal.
  • We retrieved 24 anal squamous carcinomas, 68 colorectal adenocarcinomas (including a tissue microarray), and 32 colorectal neuroendocrine carcinomas from the archives at the University of Michigan, and immunostained them for the p63 antigen.
  • We report that the p63 immunostain is a highly specific and useful tool in the diagnosis of carcinomas of the anal canal.
  • [MeSH-minor] Carcinoid Tumor / diagnosis. Carcinoid Tumor / metabolism. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Carcinoma, Neuroendocrine / diagnosis. Carcinoma, Neuroendocrine / metabolism. Colorectal Neoplasms / metabolism. Colorectal Neoplasms / pathology. Diagnosis, Differential. Humans. Predictive Value of Tests. Tissue Array Analysis. Transcription Factors

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • SciCrunch. KEGG: Data: Disease Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17255774.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


78. Olesen SH, Christensen LL, Sørensen FB, Cabezón T, Laurberg S, Orntoft TF, Birkenkamp-Demtröder K: Human FK506 binding protein 65 is associated with colorectal cancer. Mol Cell Proteomics; 2005 Apr;4(4):534-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human FK506 binding protein 65 is associated with colorectal cancer.
  • We initiated the present study to identify new genes associated with colorectal cancer.
  • Here we describe this gene hFKBP10 together with its encoded protein hFKBP65 as a novel marker associated with colorectal cancer.
  • Analysis of 31 colorectal adenocarcinomas and 14 normal colorectal mucosa by RealTime PCR for hFKBP10 showed a significant up-regulation in tumors, when compared with normal mucosa.
  • Immunohistochemical analysis of 26 adenocarcinomas and matching normal mucosa, as well as benign hyperplastic polyps and adenomas, using a monoclonal anti-hFKBP65 antibody, showed that the protein was not present in normal colorectal epithelial cells, but strongly expressed in the tumor cells of colorectal cancer.
  • In conclusion, the protein hFKBP65 is associated with colorectal cancer, and we hypothesize the protein to be involved in fibroblast and transformed epithelial cell-specific protein synthesis in the endoplasmic reticulum.
  • [MeSH-major] Adenocarcinoma / metabolism. Colorectal Neoplasms / metabolism. Tacrolimus Binding Proteins / metabolism

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15671042.001).
  • [ISSN] 1535-9476
  • [Journal-full-title] Molecular & cellular proteomics : MCP
  • [ISO-abbreviation] Mol. Cell Proteomics
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; EC 5.2.1.- / Tacrolimus Binding Proteins
  •  go-up   go-down


79. Katkoori VR, Suarez-Cuervo C, Shanmugam C, Jhala NC, Callens T, Messiaen L, Posey J 3rd, Bumpers HL, Meleth S, Grizzle WE, Manne U: Bax expression is a candidate prognostic and predictive marker of colorectal cancer. J Gastrointest Oncol; 2010 Dec;1(2):76-89
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bax expression is a candidate prognostic and predictive marker of colorectal cancer.
  • OBJECTIVE: Since the anti-tumor activity of 5-fluorouracil (5-FU) is due to induction of apoptosis, we assessed the value of expression of key apoptotic molecules (Bax, Bcl-2 and p53) in predicting the efficacy of 5-FU therapy for colorectal adenocarcinomas (CRCs).

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2002 Apr 1;98(4):498-504 [11920608.001]
  • [Cites] Ann Surg Oncol. 2001 Jul;8(6):533-7 [11456053.001]
  • [Cites] Eur J Cancer. 2002 Jul;38(11):1429-36 [12110487.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1735-43 [11919229.001]
  • [Cites] Nature. 1992 Jul 2;358(6381):15-6 [1614522.001]
  • [Cites] Oncogene. 1995 Oct 5;11(7):1217-28 [7478541.001]
  • [Cites] Cancer Res. 1995 Oct 1;55(19):4471-8 [7671262.001]
  • [Cites] N Engl J Med. 1995 Jun 1;332(22):1521-2 [7739705.001]
  • [Cites] Cell. 1993 Sep 24;74(6):957-67 [8402885.001]
  • [Cites] Cancer Res. 1996 Apr 15;56(8):1834-41 [8620501.001]
  • [Cites] J Natl Cancer Inst. 1996 Aug 7;88(15):1054-9 [8683636.001]
  • [Cites] J Pathol. 1996 Mar;178(3):264-7 [8778330.001]
  • [Cites] Br J Cancer. 1997;75(3):427-31 [9020491.001]
  • [Cites] J Natl Cancer Inst. 1997 Apr 16;89(8):585-6 [9106651.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2345-9 [9122197.001]
  • [Cites] Int J Cancer. 1997 Jun 20;74(3):346-58 [9221816.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Nov 17;240(2):376-81 [9388485.001]
  • [Cites] Cancer Res. 1998 Mar 15;58(6):1149-58 [9515799.001]
  • [Cites] Clin Cancer Res. 1998 May;4(5):1243-50 [9607583.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jun 1;41(3):585-91 [9635706.001]
  • [Cites] Cancer Chemother Pharmacol. 1998;42 Suppl:S75-9 [9750034.001]
  • [Cites] Clin Cancer Res. 1995 Oct;1(10):1103-10 [9815900.001]
  • [Cites] Clin Cancer Res. 1996 Oct;2(10):1649-57 [9816112.001]
  • [Cites] Cancer. 1998 Dec 15;83(12):2456-67 [9874449.001]
  • [Cites] Oncol Rep. 1999 Mar-Apr;6(2):365-9 [10023006.001]
  • [Cites] Biotechniques. 1999 Feb;26(2):198-200 [10023524.001]
  • [Cites] Mol Pathol. 1998 Oct;51(5):254-61 [10193519.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1364-74 [10334520.001]
  • [Cites] Oncology. 2000;58(1):52-9 [10644941.001]
  • [Cites] Histopathology. 2000 Feb;36(2):121-6 [10672056.001]
  • [Cites] Arch Pathol Lab Med. 2000 Jul;124(7):979-94 [10888773.001]
  • [Cites] BMJ. 2000 Sep 2;321(7260):531-5 [10968812.001]
  • [Cites] Clin Cancer Res. 2001 Nov;7(11):3495-503 [11705868.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):811-6 [11821465.001]
  • [Cites] Hematol Oncol Clin North Am. 2002 Aug;16(4):969-94 [12418058.001]
  • [Cites] Br Med Bull. 2002;64:1-25 [12421722.001]
  • [Cites] Br Med Bull. 2002;64:59-74 [12421725.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):241-50 [12525515.001]
  • [Cites] Eur J Cancer. 2003 Apr;39(6):718-27 [12651195.001]
  • [Cites] Oncogene. 2003 Dec 8;22(56):9030-40 [14663481.001]
  • [Cites] Cancer Lett. 2004 Feb 10;204(1):97-104 [14744539.001]
  • [Cites] Clin Cancer Res. 2004 Mar 1;10(5):1743-52 [15014027.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1564-71 [15051756.001]
  • [Cites] Cancer Lett. 2004 Jul 8;210(1):101-9 [15172127.001]
  • [Cites] Tumour Biol. 2004 Sep-Dec;25(5-6):258-63 [15627889.001]
  • [Cites] Dis Markers. 2005;21(1):1-2 [15735317.001]
  • [Cites] Am J Clin Pathol. 2005 Apr;123(4):562-70 [15743744.001]
  • [Cites] J Clin Oncol. 2005 Jul 10;23(20):4545-52 [16002846.001]
  • [Cites] Clin Cancer Res. 2005 Aug 1;11(15):5451-61 [16061861.001]
  • [Cites] Br J Cancer. 2007 May 7;96(9):1409-18 [17426704.001]
  • [Cites] Int J Colorectal Dis. 2009 Jun;24(6):655-63 [19221769.001]
  • [Cites] Int J Cancer. 2000 Sep 20;89(5):423-30 [11008204.001]
  • [Cites] Br J Cancer. 2000 Nov;83(10):1380-6 [11044365.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):4017-25 [11051251.001]
  • [Cites] Jpn J Cancer Res. 2000 Dec;91(12):1264-8 [11123425.001]
  • [Cites] Arch Pathol Lab Med. 2001 Jan;125(1):91-8 [11151060.001]
  • [Cites] Cancer Lett. 2001 Mar 10;164(1):77-84 [11166918.001]
  • [Cites] Br J Cancer. 2001 Mar 2;84(5):651-8 [11237386.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1865-78 [11251019.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2272-81 [11304781.001]
  • [Cites] Acta Oncol. 2001;40(2-3):282-308 [11441937.001]
  • [Cites] Int J Cancer. 2002 Jun 1;99(4):589-96 [11992551.001]
  • (PMID = 22811811.001).
  • [ISSN] 2219-679X
  • [Journal-full-title] Journal of gastrointestinal oncology
  • [ISO-abbreviation] J Gastrointest Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA098932; United States / NCI NIH HHS / CA / R03 CA139629; United States / NCI NIH HHS / CA / U54 CA118638; United States / NCI NIH HHS / CA / U54 CA118948
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC3397579
  • [Keywords] NOTNLM ; 5-Flurouracil / Bax / colorectal adenocarcinoma / predictive marker
  •  go-up   go-down


80. English DR, Young JP, Simpson JA, Jenkins MA, Southey MC, Walsh MD, Buchanan DD, Barker MA, Haydon AM, Royce SG, Roberts A, Parry S, Hopper JL, Jass JJ, Giles GG: Ethnicity and risk for colorectal cancers showing somatic BRAF V600E mutation or CpG island methylator phenotype. Cancer Epidemiol Biomarkers Prev; 2008 Jul;17(7):1774-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ethnicity and risk for colorectal cancers showing somatic BRAF V600E mutation or CpG island methylator phenotype.
  • Colorectal cancers arising from serrated polyps are characterized by the CpG island methylator phenotype (CIMP) and somatic mutation (V600E) in the BRAF proto-oncogene.
  • Colorectal adenocarcinomas were identified from population-based cancer registries.
  • Hazard ratios (HR) and 95% confidence intervals (95% CI) were estimated by Cox regression with adjustment for risk factors for colorectal cancer.
  • During follow-up, 718 participants were diagnosed with colorectal cancer.
  • After adjustment for other risk factors, when compared with people of Anglo-Celtic origin, those of southern European origin had lower incidence of colorectal cancer that had CIMP (HR, 0.32; 95% CI, 0.16-0.67) or BRAF mutations (HR, 0.30; 95% CI, 0.16-0.58) but similar incidence of colorectal cancer without CIMP (HR, 0.86; 95% CI, 0.70-1.05) or BRAF (HR, 0.90; 95% CI, 0.74-1.11).
  • People of southern European origin had lower risk of colorectal cancers with CIMP and BRAF mutation than people of Anglo-Celtic origin, which may in part be due to genetic factors that are less common in people of southern European origin.
  • [MeSH-major] Colorectal Neoplasms / ethnology. CpG Islands / genetics. DNA, Neoplasm / genetics. Ethnic Groups. Mutation. Proto-Oncogene Proteins B-raf / genetics

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18628431.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


81. Aparicio T, Navazesh A, Boutron I, Bouarioua N, Chosidow D, Mion M, Choudat L, Sobhani I, Mentré F, Soulé JC: Half of elderly patients routinely treated for colorectal cancer receive a sub-standard treatment. Crit Rev Oncol Hematol; 2009 Sep;71(3):249-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Half of elderly patients routinely treated for colorectal cancer receive a sub-standard treatment.
  • BACKGROUND: Several database studies report a lack of care in elderly patients with colorectal cancer.
  • PURPOSE: To describe the management of elderly patients admitted for colorectal cancer; to identify factors associated with standard management according to recommendations and to study factors influencing the survival.
  • PATIENTS AND METHODS: All consecutive patients over 75 years managed for a colorectal adenocarcinoma in our hospital from 1995 to 2000 and followed until 2006 were retrospectively included.
  • [MeSH-major] Aged / statistics & numerical data. Antineoplastic Protocols / standards. Carcinoma / therapy. Colorectal Neoplasms / therapy


82. Lima CS, Nascimento H, Bonadia LC, Teori MT, Coy CS, Góes JR, Costa FF, Bertuzzo CS: Polymorphisms in methylenetetrahydrofolate reductase gene (MTHFR) and the age of onset of sporadic colorectal adenocarcinoma. Int J Colorectal Dis; 2007 Jul;22(7):757-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphisms in methylenetetrahydrofolate reductase gene (MTHFR) and the age of onset of sporadic colorectal adenocarcinoma.
  • BACKGROUND AND AIMS: Evidence is accumulating for a role of folate in the aetiology of colorectal cancer (CRC).
  • MATERIALS AND METHODS: Genomic DNA from 102 sporadic colorectal adenocarcinoma (SCA) patients and 300 controls was analyzed by polymerase chain reaction followed by restriction digestion for the polymorphisms analyses.
  • [MeSH-major] Adenocarcinoma. Colorectal Neoplasms. DNA, Neoplasm / genetics. Methylenetetrahydrofolate Reductase (NADPH2) / genetics. Polymorphism, Genetic

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Nutr. 1999 Feb;129(2S Suppl):560S-564S [10064332.001]
  • [Cites] Am J Hum Genet. 2000 Aug;67(2):444-61 [10873790.001]
  • [Cites] Am J Epidemiol. 2004 Mar 1;159(5):423-43 [14977639.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):743-8 [12576444.001]
  • [Cites] J Nutr. 1999 Sep;129(9):1656-61 [10460200.001]
  • [Cites] JAMA. 2002 Oct 23-30;288(16):2023-31 [12387655.001]
  • [Cites] Am J Hum Genet. 1998 May;62(5):1044-51 [9545395.001]
  • [Cites] Genet Test. 1999;3(2):233-6 [10464674.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1611-21 [12496052.001]
  • [Cites] Lancet. 1997 May 31;349(9065):1591-3 [9174561.001]
  • [Cites] J Nutr Biochem. 1999 Feb;10(2):66-88 [15539274.001]
  • [Cites] Br J Cancer. 1996 Apr;73(8):902-8 [8611424.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Oct;7(10):901-6 [9796635.001]
  • [Cites] Rev Gastroenterol Mex. 2001 Jan-Mar;66(1):32-7 [11464627.001]
  • [Cites] Cancer Res. 1996 Nov 1;56(21):4862-4 [8895734.001]
  • [Cites] Nat Genet. 1999 Feb;21(2):163-7 [9988266.001]
  • [Cites] Rev Saude Publica. 2000 Feb;34(1):50-5 [10769361.001]
  • [Cites] Cancer Causes Control. 2002 Apr;13(3):239-48 [12020105.001]
  • [Cites] Nat Genet. 1995 May;10(1):111-3 [7647779.001]
  • [Cites] Gastroenterology. 2003 May;124(5):1240-8 [12730865.001]
  • [Cites] Am J Clin Nutr. 1997 Jan;65(1):46-52 [8988912.001]
  • [Cites] Pharmacogenetics. 2002 Jun;12(4):339-42 [12042673.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Nov;11(11):1332-52 [12433710.001]
  • [Cites] World J Gastroenterol. 2005 Jan 21;11(3):331-5 [15637738.001]
  • [Cites] J Nutr. 2003 Nov;133(11 Suppl 1):3748S-3753S [14608109.001]
  • [Cites] Cancer Res. 1997 Mar 15;57(6):1098-102 [9067278.001]
  • [Cites] Nat Genet. 2003 Feb;33(2):177-82 [12524541.001]
  • [Cites] Ann Surg. 1954 Jun;139(6):846-52 [13159135.001]
  • [Cites] Nat Genet. 2001 Nov;29(3):306-9 [11600885.001]
  • [Cites] Br Med Bull. 1999;55(3):578-92 [10746348.001]
  • [Cites] Clin Genet. 1998 Sep;54(3):210-4 [9788723.001]
  • [Cites] Am J Med Genet. 1999 Aug 20;88(4):311-23 [10402496.001]
  • [Cites] Am J Hum Genet. 2001 Jan;68(1):281-6 [11090340.001]
  • [Cites] Cancer. 1994 Aug 1;74(3):893-9 [8039116.001]
  • [Cites] Swiss Med Wkly. 2001 Sep 22;131(37-38):539-49 [11759174.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Jun;8(6):513-8 [10385141.001]
  • [Cites] Rev Assoc Med Bras (1992). 1992 Jul-Sep;38(3):138-44 [1340363.001]
  • [Cites] Gut. 2002 Apr;50(4):520-4 [11889073.001]
  • [Cites] Eur J Cancer Prev. 2002 Feb;11(1):105-10 [11917217.001]
  • (PMID = 17111187.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2)
  •  go-up   go-down


83. Selvakumar P, Sharma RK: Role of calpain and caspase system in the regulation of N-myristoyltransferase in human colon cancer (Review). Int J Mol Med; 2007 May;19(5):823-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of calpain and caspase system in the regulation of N-myristoyltransferase in human colon cancer (Review).
  • Our findings provide the first evidence of higher expression of NMT2 in human colorectal adenocarcinomas and the interaction of both forms of NMT with various signaling molecules.
  • In this review, we summarize the recent findings on NMT2 in human colon cancer in our laboratory.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17390089.001).
  • [ISSN] 1107-3756
  • [Journal-full-title] International journal of molecular medicine
  • [ISO-abbreviation] Int. J. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Tumor Suppressor Proteins; EC 2.3.- / Acyltransferases; EC 2.3.1.97 / glycylpeptide N-tetradecanoyltransferase; EC 3.4.22.- / Calpain; EC 3.4.22.- / Caspases
  • [Number-of-references] 52
  •  go-up   go-down


84. Arai T, Kasahara I, Sawabe M, Kanazawa N, Kuroiwa K, Honma N, Aida J, Takubo K: Microsatellite-unstable mucinous colorectal carcinoma occurring in the elderly: comparison with medullary type poorly differentiated adenocarcinoma. Pathol Int; 2007 Apr;57(4):205-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microsatellite-unstable mucinous colorectal carcinoma occurring in the elderly: comparison with medullary type poorly differentiated adenocarcinoma.
  • Mucinous carcinoma and poorly differentiated adenocarcinoma of the large intestine have a high frequency of microsatellite instability, and their occurrence increases gradually with age.
  • To elucidate the clinicopathological and immunohistochemical features of microsatellite-unstable mucinous carcinoma and compare the tumor with medullary type poorly differentiated adenocarcinoma, the clinicopathological status and expression of mucin core and hMLH1 proteins were studied in 15 microsatellite-unstable and 20 microsatellite-stable mucinous colorectal carcinomas occurring in elderly patients, and compared with 23 cases of medullary type poorly differentiated adenocarcinoma in which 21 cases were microsatellite-unstable.
  • Compared with microsatellite-stable mucinous carcinoma, microsatellite-unstable mucinous carcinomas were significantly associated with a proximal location, intra- and peritumoral inflammatory cell infiltration, frequent MUC5AC expression, a low incidence of lymph node metastasis and absent hMLH1 protein expression, which is not different to medullary type poorly differentiated adenocarcinoma except for MUC2 expression and age-related occurrence.
  • These results suggest that microsatellite-unstable mucinous carcinoma occurring in the elderly shares clinicopathological and molecular features with medullary type poorly differentiated adenocarcinoma and that microsatellite instability with absent hMLH1 expression plays an important role in the development of these two carcinomas.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma, Mucinous / genetics. Aging / genetics. Carrier Proteins / metabolism. Colorectal Neoplasms / genetics. Microsatellite Instability. Nuclear Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17316416.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Carrier Proteins; 0 / DNA, Neoplasm; 0 / MLH1 protein, human; 0 / MUC5AC protein, human; 0 / Mucin 5AC; 0 / Mucins; 0 / Nuclear Proteins
  •  go-up   go-down


85. Cubas R, Zhang S, Li M, Chen C, Yao Q: Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway. Mol Cancer; 2010;9:253
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The activation of ERK was also observed in human pancreatic ductal epithelial cells and colorectal adenocarcinoma cells overexpressing human Trop2.
  • [MeSH-minor] Animals. Cell Cycle / genetics. Cell Cycle / physiology. Cell Line. Cell Line, Tumor. Cell Proliferation. Colorectal Neoplasms / genetics. Colorectal Neoplasms / metabolism. Colorectal Neoplasms / pathology. Cyclin D1 / genetics. Cyclin D1 / metabolism. Cyclin E / genetics. Cyclin E / metabolism. Female. HCT116 Cells. Humans. Immunohistochemistry. Mice. Mice, Nude. Pancreatic Neoplasms / genetics. Pancreatic Neoplasms / metabolism. Pancreatic Neoplasms / pathology


86. Sato T, Nakashima A, Guo L, Coffman K, Tamanoi F: Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer. Oncogene; 2010 May 6;29(18):2746-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • S2215Y was identified in large intestine adenocarcinoma whereas R2505P was identified in renal cell carcinoma. mTOR complex 1 prepared from cells expressing the mutant mTOR after nutrient starvation still retains the activity to phosphorylate 4E-BP1 in vitro.

  • COS Scholar Universe. author profiles.
  • Addgene Non-profit plasmid repository. clones/clone libraries - Get Article's Plasmids - Addgene (subscription/membership/fee required).
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. SIROLIMUS .
  • Hazardous Substances Data Bank. N-BUTYL ALCOHOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • eagle-i research resources. PMID 20190810 (Special Collections) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2009 May 8;284(19):12783-91 [19299511.001]
  • [Cites] Eur J Biochem. 2002 Jun;269(12):3076-85 [12071973.001]
  • [Cites] Oncogene. 2004 Jul 22;23(33):5654-63 [15133498.001]
  • [Cites] Chem Biol. 2004 Aug;11(8):1043-51 [15324805.001]
  • [Cites] Biochim Biophys Acta. 2005 Nov 25;1756(2):81-2 [16269215.001]
  • [Cites] Chem Phys Lipids. 1996 May 24;80(1-2):117-32 [8681423.001]
  • [Cites] Nat Genet. 2005 Jan;37(1):19-24 [15624019.001]
  • [Cites] Cell. 2006 Feb 10;124(3):471-84 [16469695.001]
  • [Cites] Nat Rev Cancer. 2006 Sep;6(9):729-34 [16915295.001]
  • [Cites] Oncogene. 2006 Oct 16;25(48):6373-83 [17041623.001]
  • [Cites] J Urol. 2007 Jan;177(1):346-52 [17162089.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3514-9 [17360675.001]
  • [Cites] Mol Cell. 2007 Mar 23;25(6):903-15 [17386266.001]
  • [Cites] Cancer Cell. 2007 Jul;12(1):9-22 [17613433.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):4964-73 [17785546.001]
  • [Cites] Trends Mol Med. 2007 Oct;13(10):433-42 [17905659.001]
  • [Cites] Cell Cycle. 2007 Dec 15;6(24):3039-42 [18073536.001]
  • [Cites] J Invest Dermatol. 2008 Apr;128(4):980-7 [17914450.001]
  • [Cites] J Biol Chem. 2008 Nov 14;283(46):31861-70 [18812319.001]
  • [Cites] Anticancer Agents Med Chem. 2008 Dec;8(8):818-24 [19075563.001]
  • [Cites] Mol Cell Biol. 2009 Mar;29(6):1411-20 [19114562.001]
  • [Cites] Trends Cell Biol. 2009 Jun;19(6):260-7 [19419870.001]
  • [Cites] Science. 2001 Nov 30;294(5548):1942-5 [11729323.001]
  • (PMID = 20190810.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA041996-25; United States / NCI NIH HHS / CA / R01 CA041996; United States / NCI NIH HHS / CA / CA41996; United States / NCI NIH HHS / CA / R01 CA041996-25
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / Multiprotein Complexes; 0 / Proteins; 0 / Transcription Factors; 0 / mechanistic target of rapamycin complex 1; 8PJ61P6TS3 / 1-Butanol; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.1 / Ribosomal Protein S6 Kinases, 70-kDa; EC 2.7.11.1 / ribosomal protein S6 kinase, 70kD, polypeptide 1; EC 3.1.3.48 / CDC25A protein, human; EC 3.1.3.48 / cdc25 Phosphatases; W36ZG6FT64 / Sirolimus
  • [Other-IDs] NLM/ NIHMS225499; NLM/ PMC2953941
  •  go-up   go-down


87. Zhou JN, Chen SQ, Zhang XM, Zhou X, Zhu M, Feng B, Li JT, Ma GJ, Zhang YY: [A novel APC gene germline mutation in a familial adenomatous polyposis pedigree]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Aug;23(4):388-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The diagnosis of a patient with FAP was validated by colonoscopy, pathology and the family history.
  • This mutation manifested an aggressive form of FAP with early onset of colorectal adenocarcinoma and colonic adenoma.

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • Genetic Alliance. consumer health - Familial Polyposis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16883523.001).
  • [ISSN] 1003-9406
  • [Journal-full-title] Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
  • [ISO-abbreviation] Zhonghua Yi Xue Yi Chuan Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Adenomatous Polyposis Coli Protein
  •  go-up   go-down


88. Liu M, Imam H, Oberg K, Zhou Y: Gene transfer of vasostatin, a calreticulin fragment, into neuroendocrine tumor cells results in enhanced malignant behavior. Neuroendocrinology; 2005;82(1):1-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Burkitt lymphoma cell line, CA46, colorectal adenocarcinoma cell line, SW480, as well as endothelial cells PAE and SVEC4 were used for evaluating the function of vasostatin.


89. Chen L, Zhu YY, Zhang XJ, Wang GL, Li XY, He S, Zhang JB, Zhu JW: TSPAN1 protein expression: a significant prognostic indicator for patients with colorectal adenocarcinoma. World J Gastroenterol; 2009 May 14;15(18):2270-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TSPAN1 protein expression: a significant prognostic indicator for patients with colorectal adenocarcinoma.
  • AIM: To determine if TSPAN1 overexpression is associated with clinicopathological and prognostic factors in human colorectal adenocarcinoma.
  • METHODS: Total RNA was extracted in 20 human adenocarcinoma tissues for TSPAN1 mRNA assay by RT-PCR.
  • Eighty-eight specimens of human colorectal adenocarcinoma were surgically removed.
  • The light density of TSPAN1 mRNA expression levels was 0.89 +/- 0.30 in adenocarcinoma by gel-image system.
  • TSPAN1 protein expression was detected in 78.41% (69/88) and weakly expressed in 40% normal colorectal tissues.
  • There were significant differences between colorectal adenocarcinoma and normal control epithelium (P < 0.05).
  • TSPAN1 protein expression in colorectal cancerous tissue was significantly correlated with the histological grade, cell expression PCNA, lymph nodal metastasis and TNM staging of the disease.
  • Furthermore, by multivariate analysis, TSPAN1 protein expression demonstrated an independent prognostic factor for human colorectal cancers (P < 0.05, relative risk 0.755; 95% confidence interval 0.302-1.208).
  • CONCLUSION: The expression of TSPAN1 gene is increased in colorectal carcinoma, suggesting that TSPAN1 might serve as an independent prognostic factor for the colorectal adenocarcinoma patients.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Biomarkers, Tumor. Colorectal Neoplasms / genetics. Colorectal Neoplasms / metabolism. Membrane Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochim Biophys Acta. 2000 Mar 16;1478(1):159-63 [10719184.001]
  • [Cites] Tumori. 2008 Jul-Aug;94(4):531-8 [18822690.001]
  • [Cites] Am J Gastroenterol. 2000 Jun;95(6):1576-80 [10894600.001]
  • [Cites] J Clin Pathol. 2002 Jan;55(1):17-21 [11825918.001]
  • [Cites] Int J Cancer. 2002 Jun 20;99(6):771-5 [12115476.001]
  • [Cites] Oncogene. 2002 Oct 3;21(44):6740-50 [12360401.001]
  • [Cites] J Cancer Epidemiol Prev. 2002;7(3):143-6 [12665213.001]
  • [Cites] Ann Oncol. 2003 Jul;14(7):1026-38 [12853343.001]
  • [Cites] Cancer. 2004 Jul 1;101(1):3-27 [15221985.001]
  • [Cites] Rom J Gastroenterol. 2004 Sep;13(3):223-31 [15470536.001]
  • [Cites] Histopathology. 1981 Mar;5(2):141-63 [7216178.001]
  • [Cites] J Biol Chem. 1988 Jul 25;263(21):10175-9 [2899075.001]
  • [Cites] Cancer. 1996 Dec 1;78(11):2313-7 [8941000.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Aug;7(8):661-6 [9718217.001]
  • [Cites] Oncol Rep. 1999 May-Jun;6(3):527-31 [10203586.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Mod Pathol. 2006 Jan;19(1):59-68 [16118624.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Mod Pathol. 2006 Sep;19(9):1261-9 [16799479.001]
  • [Cites] Mod Pathol. 2007 Mar;20(3):331-8 [17277767.001]
  • [Cites] Mod Pathol. 2007 Feb;20(2):159-66 [17361204.001]
  • [Cites] Int J Surg Pathol. 2007 Oct;15(4):346-53 [17913940.001]
  • [Cites] Cancer Res. 2000 Mar 15;60(6):1677-82 [10749139.001]
  • (PMID = 19437569.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Membrane Proteins; 0 / RNA, Messenger; 0 / TSPAN1 protein, human; 0 / Tetraspanins
  • [Other-IDs] NLM/ PMC2682244
  •  go-up   go-down


90. Chen YJ, Kuo CD, Tsai YM, Yu CC, Wang GS, Liao HF: Norcantharidin induces anoikis through Jun-N-terminal kinase activation in CT26 colorectal cancer cells. Anticancer Drugs; 2008 Jan;19(1):55-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Norcantharidin induces anoikis through Jun-N-terminal kinase activation in CT26 colorectal cancer cells.
  • This study investigated the effect of NCTD on anoikis in CT26 colorectal adenocarcinoma cells.
  • [MeSH-major] Adenocarcinoma / drug therapy. Anoikis / drug effects. Antineoplastic Agents / pharmacology. Bicyclo Compounds, Heterocyclic / pharmacology. Colorectal Neoplasms / drug therapy. JNK Mitogen-Activated Protein Kinases / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BROMODEOXYURIDINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18043130.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites; 0 / Antineoplastic Agents; 0 / Bicyclo Compounds, Heterocyclic; 5442-12-6 / norcantharidin; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases; G34N38R2N1 / Bromodeoxyuridine
  •  go-up   go-down


91. Yoshikawa R, Yanagi H, Shen CS, Fujiwara Y, Noda M, Yagyu T, Gega M, Oshima T, Yamamura T, Okamura H, Nakano Y, Morinaga T, Hashimoto-Tamaoki T: ECA39 is a novel distant metastasis-related biomarker in colorectal cancer. World J Gastroenterol; 2006 Sep 28;12(36):5884-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ECA39 is a novel distant metastasis-related biomarker in colorectal cancer.
  • AIM: To investigate the possible role of polysaccharide-K (PSK) -related markers in predicting distant metastasis and in the clinical outcome of colorectal cancer (CRC).
  • METHODS: Firstly, we used protein microarrays to analyze the in vitro expression profiles of potential PSK-related markers in the human colorectal adenocarcinoma cell line SW480, which carries a mutant p53 gene.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Colorectal Neoplasms / metabolism. Neoplasm Metastasis / genetics. Transaminases / metabolism

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 Sep 15;89(6):1228-35 [11002217.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(13):2515-21 [10893281.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jul 9;99(14):9433-8 [12093899.001]
  • [Cites] J Natl Cancer Inst. 2003 Sep 3;95(17):1276-99 [12953083.001]
  • [Cites] Br J Cancer. 2003 Nov 3;89(9):1757-65 [14583781.001]
  • [Cites] Br J Cancer. 2004 Mar 8;90(5):1003-10 [14997197.001]
  • [Cites] Expert Rev Anticancer Ther. 2004 Apr;4(2):289-302 [15056059.001]
  • [Cites] Int J Immunopharmacol. 1983;5(1):35-42 [6220984.001]
  • [Cites] Cancer Immunol Immunother. 1986;22(3):181-5 [3731203.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] Nucleic Acids Res. 1990 Nov 25;18(22):6709 [2251142.001]
  • [Cites] Cancer Immunol Immunother. 1991;32(6):335-41 [1901030.001]
  • [Cites] Lymphokine Res. 1990 Winter;9(4):475-83 [2090874.001]
  • [Cites] Cell Growth Differ. 1993 Feb;4(2):57-65 [8494784.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Aug 15;90(16):7804-8 [8356088.001]
  • [Cites] Genes Dev. 1992 Dec;6(12B):2513-23 [1340466.001]
  • [Cites] Gastroenterology. 1994 Jan;106(1):42-8 [8276207.001]
  • [Cites] Cell Growth Differ. 1993 Nov;4(11):879-83 [8297793.001]
  • [Cites] Lancet. 1994 May 7;343(8906):1122-6 [7910230.001]
  • [Cites] Lancet. 1994 Jul 23;344(8917):233-4 [7913159.001]
  • [Cites] Am J Clin Oncol. 1995 Jun;18(3):216-22 [7747709.001]
  • [Cites] Anticancer Res. 1995 Mar-Apr;15(2):255-8 [7762991.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):7143-8 [8692959.001]
  • [Cites] Nature. 1996 Aug 8;382(6591):511-7 [8700224.001]
  • [Cites] J Biol Chem. 1996 Aug 23;271(34):20242-5 [8702755.001]
  • [Cites] Cancer Detect Prev. 1997;21(1):71-7 [9043766.001]
  • [Cites] Oncol Rep. 2004 Dec;12(6):1287-93 [15547752.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2645-54 [15728227.001]
  • [Cites] CA Cancer J Clin. 2000 Jan-Feb;50(1):7-33 [10735013.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):1029-37 [11221829.001]
  • (PMID = 17007058.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Biomarkers, Tumor; 0 / Proteoglycans; 0 / Tumor Suppressor Protein p53; 66455-27-4 / krestin; EC 2.6.1. / BCAT1 protein, human; EC 2.6.1.- / Transaminases
  • [Other-IDs] NLM/ PMC4100673
  •  go-up   go-down


92. Saltzstein SL, Behling CA: Age and time as factors in the left-to-right shift of the subsite of colorectal adenocarcinoma: a study of 213,383 cases from the California Cancer Registry. J Clin Gastroenterol; 2007 Feb;41(2):173-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Age and time as factors in the left-to-right shift of the subsite of colorectal adenocarcinoma: a study of 213,383 cases from the California Cancer Registry.
  • GOALS: Using a data set of more than 200,000 cases, we can measure the effects of age, time, sex, and race/ethnicity on the shift of the site of origin of colorectal adenocarcinoma from the left to the right side.
  • BACKGROUND: As people become older, there is a shift of the site of origin of adenocarcinoma of the colorectum from the left to the right side.
  • Although some studies do show some relationship of this shift, in addition to age, to race/ethnicity and to sex, there are no large, total population-based data studying the effects of these factors and time trends in this shift.
  • STUDY: 213,383 cases of adenocarcinoma of the colorectum for the years 1988 to 2003 from the California Cancer Registry have been studied.
  • RESULTS: The left-to-right shift increases significantly with increasing age and year of diagnosis, and is greater in women than in men and is greater in whites than in other racial/ethnic groups.
  • The time-related shift is a reflection of a lesser decrease in the incidence of colorectal adenocarcinoma on the right side than on the left.
  • [MeSH-major] Adenocarcinoma / pathology. Aging. Colorectal Neoplasms / pathology. Registries

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17245216.001).
  • [ISSN] 0192-0790
  • [Journal-full-title] Journal of clinical gastroenterology
  • [ISO-abbreviation] J. Clin. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


93. Kong KV, Leong WK, Ng SP, Nguyen TH, Lim LH: Osmium carbonyl clusters: a new class of apoptosis inducing agents. ChemMedChem; 2008 Aug;3(8):1269-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Osmium carbonyl clusters, especially the cluster [Os(3)(CO)(10)(NCCH(3))(2)], were found to be active against four cancer cell lines, namely, ER+ breast carcinoma (MCF-7), ER- breast carcinoma (MDA-MB-231), metastatic colorectal adenocarcinoma (SW620), and hepatocarcinoma (Hep G2).

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. OSMIUM COMPOUNDS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18433076.001).
  • [ISSN] 1860-7187
  • [Journal-full-title] ChemMedChem
  • [ISO-abbreviation] ChemMedChem
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Osmium Compounds
  •  go-up   go-down


94. Chen Y, Zhang CL, Shen YQ, Wang LC: Bioinformatics Analysis and Validation of the Expressed Sequences Tag in Human Colorectal Adenocarcinoma. Gastroenterology Res; 2009 Apr;2(2):110-114
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bioinformatics Analysis and Validation of the Expressed Sequences Tag in Human Colorectal Adenocarcinoma.
  • BACKGROUND: This study was to investigate some new pathological genes in colorectal adenocarcinoma of human.
  • METHODS: Human colorectal adenocarcinoma tissues and normal colorectal tissues were taken and suppression subtractive hybridization (SSH) and cDNA microarray techniques were employed.
  • RESULTS: Among these 10 EST, it has been found that ES274070, ES274071, ES274076 and ES274081 may play role in the onset of colorectal adenocarcinoma in human.
  • CONCLUSIONS: The ES274070, ES274071, ES274076 and ES274081 are related to the onset of human colorectal adenocarcinoma.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27956963.001).
  • [ISSN] 1918-2805
  • [Journal-full-title] Gastroenterology research
  • [ISO-abbreviation] Gastroenterology Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Keywords] NOTNLM ; Bioinformatic analyses / Colorectal adenocarcinoma / Expressed sequence tag
  •  go-up   go-down


95. Fan LF, Dong WG, Jiang CQ, Xia D, Liao F, Yu QF: Expression of putative stem cell genes Musashi-1 and beta1-integrin in human colorectal adenomas and adenocarcinomas. Int J Colorectal Dis; 2010 Jan;25(1):17-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of putative stem cell genes Musashi-1 and beta1-integrin in human colorectal adenomas and adenocarcinomas.
  • This study was to detect expressions of the two genes in colorectal adenomas and carcinomas and to analyze the correlation between Musashi-1 and beta1-integrin.
  • METHODS: Musashi-1 and beta1-integrin immunoreactivity was studied immunohistochemically in tissue microarray-based samples containing 69 colorectal adenocarcinomas, eight normal mucosa, and eight adenomas, and their messenger RNA (mRNA) expression level was detected by RT-PCR in resected specimens including the three types of tissue.
  • RESULTS: A percentage of 66.7% (46/69) and 59.2% (41/69) of colorectal adenocarcinomas were immunoreactive with Musashi-1 and beta1-integrin, respectively.
  • beta1-integrin expression was higher in group of adenocarcinomas than that of adenomas (P = 0.0276).
  • Significant differences of Musashi-1 and beta1-integrin mRNA expression levels were found between the normal colorectal mucosa, adenoma, and adenocarcinoma tissues (P = 0.01; P = 0.03, respectively).
  • CONCLUSIONS: Musashi-1 and beta1-integrin may be involved in human colorectal tumor carcinogenesis and progression.
  • [MeSH-major] Adenocarcinoma / genetics. Adenoma / genetics. Antigens, CD29 / genetics. Colorectal Neoplasms / genetics. Gene Expression Regulation, Neoplastic. Nerve Tissue Proteins / genetics. RNA-Binding Proteins / genetics. Stem Cells / metabolism


96. Wang LM, Kevans D, Mulcahy H, O'Sullivan J, Fennelly D, Hyland J, O'Donoghue D, Sheahan K: Tumor budding is a strong and reproducible prognostic marker in T3N0 colorectal cancer. Am J Surg Pathol; 2009 Jan;33(1):134-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor budding is a strong and reproducible prognostic marker in T3N0 colorectal cancer.
  • BACKGROUND: Tumor budding along the advancing front of colorectal adenocarcinoma is an early event in the metastatic process.
  • A reproducible, prognostic budding scoring system based on outcomes in early stage colorectal cancer has not been established.
  • DESIGN: One hundred twenty-eight T3N0M0 colorectal carcinoma patients with known outcome were identified.
  • [MeSH-major] Adenocarcinoma / pathology. Colorectal Neoplasms / pathology. Cytological Techniques / methods

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18971777.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Vidic S, Markelc B, Sersa G, Coer A, Kamensek U, Tevz G, Kranjc S, Cemazar M: MicroRNAs targeting mutant K-ras by electrotransfer inhibit human colorectal adenocarcinoma cell growth in vitro and in vivo. Cancer Gene Ther; 2010 Jun;17(6):409-19
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MicroRNAs targeting mutant K-ras by electrotransfer inhibit human colorectal adenocarcinoma cell growth in vitro and in vivo.
  • Mutations of K-ras have been found in 30-60% of colorectal carcinomas and are believed to be associated with tumor initiation, tumor progression and metastasis formation.
  • Therefore, silencing of mutant K-ras expression has become an attractive therapeutic strategy for colorectal cancer treatment.
  • The aim of our study was to investigate the effect of microRNA (miRNA) molecules directed against K-ras (miRNA-K-ras) on K-ras expression level and the growth of colorectal carcinoma cell line LoVo in vitro and in vivo.
  • The obtained results demonstrate that electrogene therapy with miRNA-K-ras molecules can be potential therapeutic strategy for treatment of colorectal cancers harboring K-ras mutations.
  • [MeSH-major] Adenocarcinoma / therapy. Colorectal Neoplasms / therapy. MicroRNAs / genetics. Mutation. ras Proteins / genetics

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20094071.001).
  • [ISSN] 1476-5500
  • [Journal-full-title] Cancer gene therapy
  • [ISO-abbreviation] Cancer Gene Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MicroRNAs; 0 / RNA, Small Interfering; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


98. Tokai H, Kawashita Y, Eguchi S, Kamohara Y, Takatsuki M, Okudaira S, Tajima Y, Hayashi T, Kanematsu T: A case of mucin producing liver metastases with intrabiliary extension. World J Gastroenterol; 2006 Aug 14;12(30):4918-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 75-year-old man was admitted to our hospital with a diagnosis of liver metastases from colon cancer.
  • Histopathological examination of the resected specimens from both operations revealed a well-differentiated adenocarcinoma with mucinous carcinoma.
  • With a tentative diagnosis of a recurrence of metastatic cancer, partial hepatectomy of S8 was performed.
  • Histological examination of the resected specimens also revealed mucinous adenocarcinoma, which had invaded into the biliary ducts, replacing and extending along its epithelium.
  • Therefore, the tumor was diagnosed as a metastatic adenocarcinoma from colonic cancer.
  • Liver metastases of colorectal adenocarcinoma sometimes invade the Glisson's triad and grow along the biliary ducts.
  • [MeSH-major] Adenocarcinoma. Bile Duct Neoplasms / metabolism. Bile Duct Neoplasms / secondary. Colonic Neoplasms / pathology. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Mucins / metabolism
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Male. Neoplasm Metastasis

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gastroenterol. 2004 Jan;39(1):72-5 [14767739.001]
  • [Cites] World J Gastroenterol. 2003 Feb;9(2):193-200 [12532430.001]
  • [Cites] AJR Am J Roentgenol. 1981 Feb;136(2):345-8 [6258409.001]
  • [Cites] Radiology. 1981 Dec;141(3):733-6 [6272354.001]
  • [Cites] Surgery. 1986 Aug;100(2):278-84 [3526605.001]
  • [Cites] World J Surg. 1987 Aug;11(4):541-7 [3630198.001]
  • [Cites] Ann Surg. 1995 Jan;221(1):74-8 [7826164.001]
  • [Cites] Dis Colon Rectum. 1996 Aug;39(8):847-51 [8756838.001]
  • [Cites] Jpn J Clin Oncol. 1997 Feb;27(1):18-21 [9070335.001]
  • [Cites] Am J Surg. 1997 Jun;173(6):467-71 [9207156.001]
  • [Cites] Cancer. 1999 Jan 1;85(1):171-7 [9921990.001]
  • [Cites] Ann Surg. 2005 May;241(5):715-22, discussion 722-4 [15849507.001]
  • [Cites] Surgery. 1999 Nov;126(5):829-34 [10568181.001]
  • [Cites] Am J Surg Pathol. 2000 Jun;24(6):870-6 [10843291.001]
  • [Cites] Pathol Int. 2002 Aug;52(8):514-8 [12366810.001]
  • [Cites] AJR Am J Roentgenol. 1978 Nov;131(5):839-42 [101040.001]
  • (PMID = 16937483.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Mucins
  • [Other-IDs] NLM/ PMC4087635
  •  go-up   go-down


99. Aljarabah MM, Borley NR, Wheeler JM: Appendiceal adenocarcinoma presenting as left-sided large bowel obstruction, a case report and literature review. Int Semin Surg Oncol; 2007;4:20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Appendiceal adenocarcinoma presenting as left-sided large bowel obstruction, a case report and literature review.
  • Herein we present a case of appendiceal adenocarcinoma presenting as left-sided large bowel obstruction, we also review the literature of unusual presentations of appendiceal tumours.
  • CASE PRESENTATION: we report a case of left sided large bowel obstruction found to be secondary to an appendiceal adenocarcinoma.
  • The patient presented with abdominal pain, distension and constipation, CT scan showed large bowel obstruction thought to be due to a sigmoid tumour, on laparotomy the appendix was also noted to be abnormal.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Abdom Imaging. 1999 Mar-Apr;24(2):193-5 [10024411.001]
  • [Cites] Surg Today. 2000;30(1):78-81 [10648090.001]
  • [Cites] Cir Cir. 2004 Sep-Oct;72(5):375-8 [15550226.001]
  • [Cites] Colorectal Dis. 2006 May;8 Suppl 1:20-4 [16594960.001]
  • [Cites] J Gastroenterol Hepatol. 2006 Jun;21(6):1079-81 [16725004.001]
  • [Cites] Dis Colon Rectum. 1998 Jan;41(1):75-80 [9510314.001]
  • [Cites] Gynecol Oncol. 1982 Apr;13(2):265-8 [7076041.001]
  • [Cites] J Urol. 1980 Jan;123(1):123 [7351705.001]
  • [Cites] Dis Colon Rectum. 1977 Mar;20(2):130-4 [844397.001]
  • [Cites] Br J Urol. 1996 Aug;78(2):305-6 [8813936.001]
  • [Cites] Br J Surg. 2006 Jul;93(7):783-92 [16775823.001]
  • (PMID = 17662117.001).
  • [ISSN] 1477-7800
  • [Journal-full-title] International seminars in surgical oncology : ISSO
  • [ISO-abbreviation] Int Semin Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1948007
  •  go-up   go-down


100. Lee EK, Han GY, Park HW, Song YJ, Kim CW: Transgelin promotes migration and invasion of cancer stem cells. J Proteome Res; 2010 Oct 1;9(10):5108-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Similar results were also observed in tumorigenic cells derived from colorectal adenocarcinoma and prostate carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20707403.001).
  • [ISSN] 1535-3907
  • [Journal-full-title] Journal of proteome research
  • [ISO-abbreviation] J. Proteome Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Glycoproteins; 0 / Microfilament Proteins; 0 / Muscle Proteins; 0 / Peptides; 0 / transgelin
  •  go-up   go-down






Advertisement